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Zinc (Zn2+) is an essential micronutrient which plays a pivotal role as a signalling, 
catalytic and structural component in cells and functions in several physiological 
processes such as immune function, wound healing, cognition, reproduction and 
as co-factor for various enzymes involved in antioxidant system of the body. It 
functions as a component of the antioxidant defence system within tissues and 
cells and has been identified as a factor of great significance in cardiovascular 
health. Obesity is a major risk factor for cardiovascular disease. It is thought that 
an abnormality in adipocyte Zn2+ transport may contribute to obesity development. 
Hypozincaemia (low Zn2+ level in blood) in an obese person is followed by a 
decrease in the systemic antioxidant status resulting in a reduced response to 
oxidative stress, while Zn2+ supplementation reduces inflammation caused by 
obesity. The connection between obesity and the outcome from an acute 
myocardial infarction (AMI) is many-sided. Both obesity and AMI have been 
associated with production of inflammatory mediators and reactive oxygen species 
(ROS), which cause cell injury and eventually cell death. The pro-inflammatory 
and pro-oxidant status associated with obesity in the presence of an AMI may 
therefore present an increased risk of morbidity and mortality. The present study 
aimed to investigate the role of Zn2+ in maintaining antioxidant status in the heart 
of both obese and non-obese settings. 
Results from biochemical assays showed that, chronic exposure of mice to a 
suboptimal level (5mg/kg) of dietary Zn2+ in combination with a high fat diet did 
not significantly alter cardiac levels of glutathione (GSH) compared with the Zn2+ 
adequate group (Zn2+ 35 mg/kg) at 15 and 25 weeks. However, the level of total 
GSH in the heart was significantly reduced by approximately 50% in the Zn2+ 
adequate group at 25 compared with 15 weeks. A suboptimal level of Zn2+ (5 
mg/kg) did not significantly affect Copper Zinc superoxide dismutase (Cu/Zn-SOD) 
activity after either 15 or 25 weeks of dietary intervention. However, heart Cu/Zn-
SOD activity was higher in all the groups at 25 compared to 15 weeks. In a second 
study in rats subjected to in vitro myocardial I/R injury, 2 weeks of severe dietary 
Zn2+ depletion (<1 mg Zn/kg diet) was associated with reduced cardiac GSH levels, 
while Cu/Zn-SOD activity was not affected by dietary Zn2+ intake. In contrast, in 
vitro acute Zn2+ depletion with TPEN reduced Cu/Zn-SOD activity, but not GSH 




content or Caspase 3 activity but plasma levels of Zn2+ were reduced following 
dietary Zn2+ depletion. 
These results demonstrate that Zn2+ depletion results in a worse outcome from I/R 
via different mechanisms, depending upon the method used to deplete ZN2+. and 
shows the protective effect of Zn2+ as a co-factor of antioxidant enzymes in 
preventing injuries caused by I/R and propose its use as a possible treatment 
against cardiovascular disease. Further studies are required to better understand 
the effect of acute or chronic Zn2+ depletion on biomarkers of antioxidant status in 
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1. The physiological role of zinc (Zn2+) 
 
1.1 Zinc (Zn2+) as an essential trace element 
In the human body, Zn2+ is the most abundant intracellular trace element and second 
most widely distributed after iron (King et al. 2006). It participates in many (>300) 
key enzyme reactions that are important in cell proliferation and differentiation, 
apoptosis, and metabolic activation (Jansen et al. 2009; Li et al. 2017). Zn2+ 
regulates gene expression and protects proteins from oxidation by binding to their 
sulfhydryl (SH) groups (Wiernsperger and Rapin 2010). A large number of proteins 
possess Zn2+ in their structure and it is the only trace element that is associated with 
all six enzyme classes in the body, the transferases, hydrolases, oxidoreductases, 
lyases, isomerases, and ligases (Valee and Falchuk 1993).  
 
1.1.1 Zn2+ storage and homeostasis 
Normal cellular activity necessitates the mobilization of Zn2+ and its transfer from 
one Zn2+-binding site to another (Feng et al. 2005), and its homeostasis is controlled 
through the Zn2+ transporters, metallothionein (MT), and permeable membranes 
(Fukada et al. 2011). Free Zn2+ does not exist in the cell at an appreciable 
concentration as the vast majority is always bound to MT, which is a well preserved 
low molecular weight, cysteine-rich protein that maintains the cellular homeostasis 
of Zn2+ (Miles et al. 2000). A number of proteins (Zn2+ transport proteins) including 
MT, regulate Zn2+ homeostasis at different levels (tissue, cellular, and subcellular) in 
the human body (Baltaci and Yuce 2018). Zn2+ is stored in discrete compartments 
inside or outside intracellular organelles and vesicles by Zn2+ transporters (ZnT and 
ZIP) as shown in Figure 1.1. In mammals, there are 14 ZIP and 9 ZnT transporter 
genes (Baltaci and Yuce 2018) (Figure 1.1) each of which, when absent or 
dysfunctional, is associated with different physiological roles and/or health problems 
(Table 1.1) (Baltaci and Yuce 2018). Both types of transporters display specific 
changes in protein stability and cellular localization in response to various stimuli 
including Zn2+ deficiency (Kimura and Kambe 2016). ZIP (Zinc/Iron Permease) 
members facilitate the influx of Zn2+ into the cytosol from the outside of cells and 
the lumen of intracellular compartments, while ZNT (Zinc Transporter) members 






Figure 1.1: Localization of ZnT and ZIP transporters at the subcellular level. TGN - 
transgolgi network; ER- endoplasmic reticulum; (adapted from Kimura and Kambe 
2016).  
  
Table 1.1: Physiological occurrences and health problems associated with ZnT and ZIP 
proteins (Kambe et al. 2014; Baltaci and Yuce 2018) 
ZnT Proteins  Physiological events and health problems 
ZnT5  Involved in cardiovascular development, the maturation of 
osteoblasts and delayed allergic reactions mediated by mast 
cells 
ZnT7  Involved in Insulin signalling pathway (Znt7-null mice 
displayed diet-induced glucose intolerance and insulin 
resistance) Huang et al. 2012. 
ZnT9  Found to be significantly lower in obesity 
ZnT10 Dysregulation contributed to disease progression in 
Alzheimer’s patients (Bosomworth et al. 2013). 
ZIP 4 Mutations in this gene causes the inherited disease 




ZIP13 This gene mutation causes Spondylocheiro dysplastic Ehlers–
Danlos syndrome (SCD-EDS) 
 
1.1.2 Role of Zn2+ as an antioxidant 
Amongst its several functions, such as a membrane stabilizer and anti-
inflammatory entity, Zn2+ has been shown to function as an antioxidant by 
protecting SH groups against oxidation and hindering ROS production in cultured 
porcine endothelial cells and 3T3 cell models, respectively (Hennig et al. 1996; 
Oteiza et al. 2000; Zhang et al. 2018). Zn2+ inhibits NADPH oxidase, resulting in 
decreased production of ROS, and induces the generation of MT, which acts as a 
free radical scavenger (Prasad 2014). Zn2+ also causes a rise in the activation of 
antioxidant enzymes such as superoxide dismutase (SOD) and catalase, prevents 
lipid peroxidation, and decreases the actions of the oxidant-promoting enzymes 
inducible nitric oxide synthase (iNOS) and NADPH oxidase (Wiernsperger and 
Rapin 2010; Prasad 2014).  Moreover, Zn2+ exerts additional antioxidant effects 
by protecting thiol groups from oxidation via complexation; a result of this is 
upregulated expression of GLC (Glutamate Cysteine Ligase), which controls the 
rate‐limiting step in glutathione (GSH) synthesis via activation of the transcription 
factor Nrf2 (Cortese et al. 2008). 
  
1.1.3 Dietary Zn2+ deficiency  
In the developing countries, nutritional Zn2+ deficiency may affect more than 2 
billion people (Prasad 2014) while in developed nations, the aged are a high-risk 
group due to poor dietary intake and reduced Zn2+ uptake with age (Haase et al. 
2008). Two to three grams of Zn2+is contained in the adult human body of which 
0.1% is replaced every day (Maret and Sandstead 2006). Some food sources 
include oysters, meat, dairy products and cereals (Kaur et al. 2014). Across the 
world, there are varying estimated average requirement (EAR) for 
nutrients,including Zn2+. EARs are the recommended average daily level of intake 
estimated to meet the needs of half of the healthy population (Lawrence and 
Robertson, 2007). In the UK, the recommended daily intake of Zn2+ for males and 
females aged 19-75+ year is 7.0mg/day (PHE 2016).   In the US and Canada, the 




EAR) is set to meet the dietary demands of the population of a sex group or in a 
given life stage; for Zn2+ it is 15 mg/day for males and 12 mg/day for females.  In 
Australia and New Zealand, the Recommended Dietary Intake (RDI) is the official 
guidance, while in the UK the Reference Nutrient Intake (RNI) is the preferred 
reference value (Lawrence and Robertson 2007). Across the Canada, New Zealand 
and Australia, the EAR for zinc ranges from 5.5 to 12 mg/day (Karen et al. 2013), 
whereas the Committee on Medical Aspects of Food and Nutrition Policy (COMA) 
set the UK Zn2+ RNI ranges at 5.5-9.5 mg/day for males and 4.0-7.0 mg/day for 
females (COMA 1991).  
 
However, approximately 30 % of the global elderly population are deficient in Zn2+,   
thus supplementation of this important nutrient in this high-risk group has been 
proposed to support homeostasis, reduce susceptibility to infections, decrease OS 
and lower inflammatory cytokine production (Prasad, 2014; Haase et al. 2007). 
Zinc supplementation studies in the elderly have been found to decrease oxidative 
stress, and generation of inflammatory cytokines suggesting that it may have a 
protective effect in atherosclerosis and cardiovascular disease (Bao et al. 2010, 
Prasad, 2014). 
 
Zn2+ cannot be stored therefore there is a need for regular intake, inadequate 
intake of Zn2+ resulting in deficiency is a risk factor for cardiovascular diseases 
(CVD) (Jansen et al. 2009).  For example, Salehifar et al. (2008) reported a trend 
of lower Zn2+ level of 0.97 ± 0.25 mg/l vs. 1.12 ± 0.42 mg/l in idiopathic dilated 
cardiomypathy (IDC) patients compared to healthy volunteers, respectively with a 
risk ratio of 0.2. This finding therefore suggests that Zn2+ imbalance plays a 
significant role in development of IDC. Similarly, a study has reported that in 
patients with congestive heart failure, both with or without atrial fibrillation (AF),  
there is a significant hypozincemia (23.2±16.8μg/dl (AF); 24.7±27.6μg/dl (non-
AF)) when compared to the normal control group who were volunteers with normal 
ejection fraction (70.9±21.6μg/dl; Ghaemian et al, 2011). 
 
1.2 Cardiovascular diseases (CVD). 
CVDs are conditions which affect the heart and blood vessels and they include 
heart conditions a person is born with, inherited disorders and conditions that 




coronary heart disease. People who are at risk of CVDs are likely to be 
overweight/obese, hypertensive, diabetic, or have abnormal lipid levels 
(dyslipidaemia) (Sjöström et al. 2007; D’agostino et al. 2008). According to the 
World Health Organisation (WHO), the number one cause of death worldwide is 
cardiovascular disease (CVD) and is estimated to be about 7.4 million (Jefferson 
and Topol 2005; WHO 2019).  Indeed, Roth et al (2017) revealed that CVD 
accounts for 31.80% of all global deaths. Of these, 85% of deaths are caused by 
heart attack (acute myocardial infarction; AMI) and stroke),. Moreover, CVD 
accounts for 82% of deaths in low- and middle-income countries and, by 2030, 
23.6 million people are estimated to die from CVDs (WHO 2019). In the UK, the 
British Heart Foundation (BHF) UK Factsheet for January 2020 states that460 
people will die daily from CVDs, and AMI has been identified as the leading cause 
of hospital admission and mortality (Moran et al. 2014; Asaria et al. 2017).  More 
than 7 million people in the UK live with CVD (BHF 2020), and around 80% of 
these will have at least one risk factor (BHF 2020).   Indeed multiple risk factors 
for CVD are more prevalent in the Western world (Jefferson and Topol 2005).  
 
1.2.1 Acute myocardial infarction (AMI)  
Myocardial infarction (MI) is a term used when there are signs suggestive of 
myocardial necrosis in the clinic alongside myocardial ischaemia (Thygesen et al. 
2007). Acute MI (AMI) is a significant cause of morbidity and mortality globally 
with a yearly ratio of 1:6 for men and 1:7 for women in Europe (Keller et al. 2018) 
and this usually results from reduced blood supply to the heart muscle as a 
consequence of either a decrease or complete obstruction of blood flow in the 
coronary arteries. This subsequently leads to ischaemia and an accumulation of 
toxic metabolites within the tissue causing loss of function and ultimately death of 
the cardiomyocytes (Jefferson and Topol 2005). AMI can be confirmed clinically by 
grouping 2 or 3 features which include chest pain, electrocardiographic (ECG) 
abnormalities (±Q wave development, ±ST segment changes) and a rise in cardiac 
enzymes (cardiac troponin and the MB fraction of creatine kinase; CK-MB) 
(Antman et al. 2000; Thygesen et al. 2012). An AMI may lead to sudden death 
due to ventricular tachyarrhythmia/fibrillation activated by ischaemia due to 
arterial occlusion resulting from the rupturing of atheromatous plaque (Davies and 





1.2.2 Energy metabolism in the myocardium (aerobic and anaerobic) 
1.2.2.1 Aerobic metabolism 
Ordinarily, the function of the heart is dependent on a continuous production of 
energy in the form of ATP by oxidative phosphorylation in the mitochondria 
(Stanley and Chandler 2002). The heart requires a high energy supply to function 
because of its constant function of pumping blood around the body to maintain 
circulation. This energy is derived from free fatty acids (FAs), ketones, 
carbohydrate (glucose and lactate) and amino acids (reviewed in Sambandam and 
Lopaschuk 2003). About 60–90% of this energy is from FA oxidation (a process 
that is highly dependent on oxygen for ATP generation) with the remainder being 
derived from glucose and lactate metabolism (Stanley and Chandler 2002). FA 
oxidation is more energy efficient with an ATP production of 42 Joules (J) compared 
to glucose with 38 J, however glucose utilisation is more oxygen efficient with 6.3 
moles of ATP consumed per O2 molecule compared to 5.5 moles of ATP per O2 
molecule for FA utilisation (Wolff et al. 2002). Under conditions of normal (aerobic) 
metabolism, FAs are converted to acyl-CoA upon entry into the cardiomyocyte.  
This is then transported into the mitochondria where it undergoes β-oxidation to 
release acetyl–CoA, which in turn enters the tricarboxylic acid cycle (TCA) cycle to 
produce ATP, CO2 and H2O (Figure 1.2). In addition, under aerobic conditions 
glucose undergoes glycolysis to give rise to pyruvate which is also oxidised in the 
mitochondria via the tricarboxylic acid (TCA) cycle, or converted to lactate. Excess 
glucose is stored as glycogen in the myocardium as an additional energy source 
for anaerobic metabolism if the demands of the heart exceed the supply of oxygen 
to the cardiomyocyte (Wolff et al. 2002; Sambandam and Lopaschuk 2003).  
 
The uptake of glucose from outside the cell is controlled by the concentration of 
glucose transporters (GLUT 1 and 4) and the glucose gradient across the 
membrane (Stanley and Chandler 2002). GLUT 1 and GLUT 4 are the predominant 
isoforms of the glucose transporter family identified in the heart and they are 
located in the intracellular vesicles and sarcolemmal membrane (Stanley and 
Chandler 2002). Therefore, the first step of glucose metabolism in the heart is its 
transport across the sarcolemma and the cardiomyocyte is able to take up glucose 
depending on the quantity of transporters in the plasma membrane (Young et al. 
1997; Russell et al. 1998). Insulin and ischaemia have been found to have an 




to the plasma membrane and this leads to a faster entrance of glucose into the 
cell (Slot et al. 1991; Sun et al. 1994; Stanley and Chandler 2002). In AMI, insulin 
enhances myocardial glucose uptake bringing about the translocation of glucose 
transporters thereby leading to an increase in glucose metabolism (Sun et al. 
1994). Apart from the heart muscle, GLUT 4 can also be found in adipocytes and 
skeletal muscle (Slot et al. 1991). Once glucose enters the cell, it is quickly 
phosphorylated to form glucose 6 phosphate and then converted either to glycogen 
or goes through the glycolytic pathway (Stanley and Chandler 2002). 
 
1.2.2.2 Anaerobic metabolism 
Myocardial ischaemia causes a striking change in metabolism leading to an 
enhanced rate of conversion of glucose to lactate as well as a switch from lactate 
being taken up by the myocardium to it being produced, causing an interference 
in cell homeostasis (Wolff et al. 2002). As a consequence of the lack of O2 supply, 
oxidation of FA and glucose in the mitochondria is impaired. The anaerobic 
glycolytic pathway is therefore activated to meet the critical energy demand of the 
heart, the main characteristic of which is the generation of ATP through the 
conversion of stored glycogen to pyruvate and H+ ions (hydrolysis). However, since 
pyruvate cannot be oxidised in the mitochondria, there is an excess accumulation 
of both lactate and H+ ions in the cytosol leading to Na+ influx via Na+/H+ 
exchanger, which subsequently leads to Ca2+ accumulation via the Na+/Ca2+ 






Figure 1.2: Schematic representation of energy utilisation of the cardiomyocyte under 
aerobic conditions, the main pathways of which are fatty acid and glucose oxidation. (TCA 




 Figure 1.3: A schematic representation of energy metabolism in the ischaemic heart. 




1.2.3 Reperfusion injury (RI) 
Reperfusion is a term used to describe the restoration of the flow of blood to the 
heart. Principally, restricted blood flow to the heart (ischaemia) causes an 
imbalance between demand and supply of O2 causing injury and an impaired 
function of the heart (Frank et al. 2012). Reperfusion is achieved clinically using 
thrombolytic treatments or the use of percutaneous coronary intervention (PCI) 
(Yellon and Hausenloy 2007). Reperfusion is the utmost effective method to 
restore ischaemic cells that are not yet apoptotic or necrotic, leading to restoration 
of function and thus causing the final infarct size sustained to be reduced (Maroko 
et al. 1972; Hausenloy and Yellon 2004). However, sudden reintroduction of 
oxygen after a period of ischaemia leads to an increased production of free radicals 
in the heart muscle (Garlick et al. 1987) and immediate cell death; this response 
to reperfusion is known as the ’oxygen paradox’’ (Maxwell and Lip 1997; Hausenloy 
and Yellon 2004; Yellon and Hausenloy 2007). This leads to the death of 
cardiomyocytes that were viable prior to reperfusion, thereby increasing the infarct 
size (Liu et al. 1996; Yellon and Hausenloy 2007). The predominant mechanisms 
involved in reperfusion injury include the O2 (oxygen) paradox, the Ca2+ (calcium) 
paradox, the pH paradox and inflammation (Yellon and Hausenloy 2007). Studies 
have shown that reperfusion-induced oxidative stress (OS) also reduces the 
amount of intracellular signalling molecules such as the cardioprotective nitric 
oxide (NO), a known antioxidant. Furthermore, sarcolemmal membrane damage 
induced by OS leads to increases in intracellular Ca2+ which results in Ca2+ overload 
and ultimately cardiac cell death (Liu et al. 1996; Yellon and Hausenloy 2007). As 
the heart continues to be reperfused, there is clearance of the accumulated lactic 
acid, the ion exchangers return to normal and the intracellular pH also rapidly 
returns to normal (Liu et al. 1996; Kloner and Jennings 2001; Yellon and 
Hausenloy 2007). In terms of cardiac energy, the re-introduction of oxygen allows 
FA oxidation to recommence, restoring ATP levels within the heart (Belke and 
Lopaschuk 1997; Sambandam and Lopaschuk 2003). Sometimes, there is a 
delayed recovery of metabolism in a previously ischaemic heart and which can 
cause a loss of function of the myocardium after recovering (Schwaiger et al. 
1985). 
Delayed RI also occurs as a result of activation and build-up of neutrophils 




cells via production of more ROS, endothelial dysfunction (ED) and plugging of 
capillaries (Hoffman et al. 2004). ED is characterized by diminished bioavailability 
of vasodilators, predominantly NO, and increased contractile factors derived from 
the endothelium supporting the development of cardiovascular disease and 
atherosclerosis (Couillard et al. 2005; Hadi et al. 2005; Fernández-Sánchez et al. 
2011) which is a consequence of both increased ROS production and decreased 
antioxidant capacity. ED can also be caused by stimulating inflammation and 
cytokines (Couillard et al. 2005). Reperfusion of the heart can therefore contribute 
to a worse outcome after a myocardial ischaemic injury accounting for up to 50% 
of the infarct’s final size (described as lethal reperfusion injury) (Frank et al. 2012).  
 
1.2.4 The reperfusion injury salvage kinase (RISK) pathway in I/R 
ROS also activate glycogen synthase kinase-3β (GSK-3β), a serine/threonine 
kinase that phosphorylates and downregulates glycogen synthase, the rate-
limiting enzyme of glycogen metabolism.  In the basal state, GSK-3β keeps the 
activities of the antiapoptotic BH4 and the “derepressor” Bcl-2 protein family 
members in check.  However, under conditions of oxidative stress this GSK-3β 
subdomain pool is inactivated, causing a shift in interaction within the mPTP-
regulatory complex in favour of the proapoptotic elements (Juhaszhiva et al. 
 2008) leading to mitochondrial permeability transition pore (mPTP) opening 
(a mechanism involved in I/R injury and cell death) (Hausenloy et al. 2002). 
Opening the mPTP permits the entrance of water and solutes into the mitochondria 
which causes an increase in the matrix volume, and ruptures the outer 
mitochondrial membrane eventually initiating apoptosis by leading to the release 
of intermembrane cytochrome C (Hausenloy et al. 2002). In contrast ischaemic 
pre-conditioning (i.e. exposure of heart tissue to a short period of ischaemia prior 
to a more prolonged ischaemic period followed by reperfusion) have been linked 
to the activation of a protective sequence of events (the reperfusion injury salvage 
kinase; RISK) pathway),  the activation of which results in activation of two key 
pro-survival kinases; extracellular-signal regulated kinase 1/2 (ERK; also referred 
to as p42/p44 MAPK) and Akt (Protein Kinase B;PKB) (Hausenloy and Yellon 2004; 
Hausenloy and Yellon 2007; Figure 1.4). PI3K/Akt activation, and subsequent 




while ERK activation results in tissue preservation via P70s5K. Both pathways have 
been demonstrated to have cardioprotective effects when activated at the time of 
reperfusion (Hausenloy and Yellon 2004). 
 
 
Figure 1.4: Schematic structure showing the 2 key pro-survival kinase pathways (1/2 ERK 
and Akt). Upregulation of the RISK pathway by means of activating these pathways 
phosphorylates downstream targets like eNOS-producing NO, which inhibits mPTP opening. 
(adapted from Tsang et al. 2004). MEK1/2: mitogen-activated protein kinase, P13: 
prosurvival kinase, Erk1/2: extracellular signal-regulated kinases. AKT/PK B: Protein 









1.2.5 Antioxidant defences within the heart 
The rapid rise in ROS and oxidative damage that occurs during reperfusion is 
caused by an imbalance in antioxidant levels and ROS production (Yamashita et 
al. 1998). This burst of ROS upon reperfusion of the ischaemic heart can lead to 
molecular damage to vital structures and functions (protein, DNA) of the heart 
(Ambrosio et al. 1993; Møller et al. 1996; Becker et al. 1999; Couillard et al. 
2005). Glutathione (GSH) works alongside superoxide dismutases (SODs) to 
remove ROS, however during OS the amount of ROS exceeds the capacity of the 
antioxidant enzymes, leading to tissue damage (Chan et al. 1998). GSH is a 
tripeptide (L-gamma--glutamyl-L- cysteinyl-glycine) antioxidant that constitutes 
the highest number of non-protein thiols in the human body (Cheung et al. 2000). 
It is oxidized to glutathione disulphide by GSH peroxidase (Anderson 1998) which 
is then regenerated from glutathione disulphide by GSH reductase. This redox 
cycle is important for the cell to combat oxidant stress (Cheung et al. 2000).  
Antioxidants (GSH and SOD) generally have two ways in which they carry out their 
actions - the immediate (acute) and the later (chronic). The immediate effect 
involves different mechanisms, amongst which are decreasing the formation of 
·OH (the hydroxyl radical) group and protecting sulfhydryl proteins from hydrogen 
peroxide (H2O2) through the antagonism of redox-active transition metals (iron 
and copper) (Powell et al. 1994). The chronic effect of GSH and SOD’s action can 
be achieved by the binding of Zn2+ directly to sulfhydryl groups of GSH and SOD, 
thereby reducing the reactivity these sulfhydryl group proteins (Powell et al. 
1994).  
SOD is an endogenous antioxidant that scavenges ROS by converting superoxide 
radicals to H2O2 and oxygen (Förstermann et al. 2017). The SOD enzymes are 
important in the detoxification of ROS by scavenging them, thus protecting against 
OS and preventing the degradation of NO by superoxide in the vascular wall (Neves 
et al. 2012). There are 3 isoforms of mammalian SOD namely (1) SOD1 
(copper/zinc-SOD; Cu/Zn-SOD) usually seen in the cytoplasm and mitochondrial 
intermembrane space; (2) SOD2 (manganese-SOD; Mn-SOD) found in the 
mitochondrial matrix, and (3) SOD3 (extracellular SOD) expressed in the 
extracellular matrix, on the cell surface, and in extracellular fluids and these 3 
isozymes have crucial antioxidant roles viz catalyst to the dismutation of 




1.2.6 Role of Zn2+ in controlling apoptosis-induced myocardial cell death 
Apoptosis (programmed cell death) also contributes to myocardial I/R (Hausenloy 
et al. 2002), the hallmark of which is activation of caspases. Cysteine aspartate 
proteases (caspases) are a family of proteases that cleave a variety of critical   
cellular proteins containing the caspase recognition site.  In the case of caspase 3 
and 7 this is essential to the apoptotic process, making all models of apoptosis to 
be characterized by increased caspase activity (Jankowski-Hennig et al. 2000). 
The caspase family of enzymes are among the major proapoptotic proteins and 
have been implicated in many biochemical pathways leading to apoptosis (Chai et 
al. 2000). Three major pathways involve (1) membrane receptor-ligand 
interactions (e.g., Fas-FasL binding) that result in activation of the upstream 
caspase, caspase-8; (2) triggering by chemical stimuli, which causes changes in 
mitochondrial membrane permeability, release of cytochrome c into the cytoplasm, 
and subsequent activation of the upstream caspase, caspase-9; and (3) activation 
of caspase-12 triggered in response to stress-induced changes in the endoplasmic 
reticulum (Chai et al. 2000).  Caspase-8 and caspase-9, triggered either directly 
or indirectly, activate the major effector caspase, caspase-3/DEVD-caspase (Chai 
et al. 2000).   
 
Zinc deficiency has been associated with the induction of apoptosis, and in order 
to aid our understanding of mechanisms by which zinc deficiency induces apoptotic 
cell death different studies have been carried out. In vitro studies have shown that 
depletion of intracellular Zn by culturing chronic lymphatic leukaemia (CLL) cells 
in Zn-depleted medium, or by treatment of cells with N,N,N',N'-tetrakis-2-
pyridylmethylethylenediamine (TPEN), results in apoptosis ( Zalewski et al. 1991, 
1993). Zn deficiency induced apoptosis is dependent on caspase-3 activation, since 
cytosolic caspase-3 activity is increased in Zn deficient cells while the specific 
caspase-3 inhibitor z-DEVD-fmk can partially suppress apoptosis (Truong-Tran et 
al. 2001). Moreover, a study carried out by Martin et al. (1991), using three human 
cell lines of lymphoid (Molt-3 and Raji) or myeloid (HL-60) origin maintained in 
vitro under zinc-sufficient or zine-deficient conditions, assessed cell proliferation, 
viability and mode of death.  Their data showed that apoptosis occurred in zinc-
deficient HL-60 and Raji cells, and was characterized by a slow decline in cell 
viability, since cells exhibited condensed and fragmented nuclear DNA and these 




manner (Martin et al. 1991). In another study, Zalewski et al (1991) 
demonstrated, in chronic lymphatic leukaemia (CLL) cells, that the intracell lular 
pool of chelatable Zn2+ blocks apoptosis and that this pool is increased by uptake 
from the medium (Zalewski et al. 1991: Zalewski, and Forbes1993). Finally, a 
study carried out by Chai et al (2000) using three human malignant epithelial cell 
lines (LIM1215 (colonic); NCI-H292 (bronchial); and A549 (alveolar type II)) 
demonstrated that, in TPEN-treated cells, depletion of Zn2+ was followed by 
activation of caspase-3, DNA fragmentation, and morphologic changes and these 
effects were completely prevented by exogenous ZnSO4 (Chai et al. 2000). 
 
Caspase 3 can also be inhibited in vivo by physiologically relevant concentrations 
of Zn2+ , since a study has shown that rat embryos collected mid-gestation from 
dams fed a Zn-deficient (0.5mgZn/g) displayed increased caspase activity 
compared to embryos from pair-fed dams, or dams fed a Zn-adequate (25mg 
Zn/g)  diet ((Jankowski-Hennig et al. 2000)). The authors of this study proposed 
that Zn-deficiency-induced apoptosis may be mediated via increased ROS 
concentrations since they also observed increased concentrations of ROS and 
apoptosis in 3T3 cells cultured in Zn-deficient medium (Jankowski-Hennig et al. 
2000). 
 
1.2.7 Role of Zn2+ in ischaemia and CVD 
The protective potential of Zn2+ in CVD has been widely reported in the literature 
(Little et al. 2010; Lee et al. 2015). With ROS causing a marked increase in free 
radicals, there is release of Zn2+ by MT from both the mitochondria and cytosol 
(Feng et al. 2005; Lin et al. 2011). This release of Zn2+ affects Ca2+ regulation in 
cardiomyocytes because electrical stimulation induces its entry through voltage 
gated Ca2+ channels and this affects intracellular Zn2+ stores (Beyersmann and 
Haase 2001). Intracellular Zn2+, when either increased or decreased, has been 
linked with apoptotic cell death (Truong-Tran et al. 2001; Viswanath et al. 2011), 
while in vitro I/R following a state of acute depletion of Zn2+ with TPEN (a Zn2+ 
chelator) has been shown to result in a greater degree of infarct size (Skene et al. 
2019). In addition, studies in an isolated heart model have demonstrated that Zn2+ 
supplementation enhances post-arrest cardiac function, which is suggestive of its 




1995). In the clinical setting, indeed, circulating Zn2+ levels have been shown to 
decrease (group mean-76-83 µg/lOO ml) within the first 3 days following an AMI 
and then begin to increase towards normal (90-118 µg/lOO ml) levels within 7-10 
(Handjani et al. 1974) and 10-14 days (Low and Ikram 1976; Huang et al. 2018). 
 
1.2.8 The role of Zn2+ in cardioprotection 
Since patients who suffer from myocardial infarction have been found to have 
depleted plasma Zn2+ levels as well as high levels of enzyme markers (creatine 
kinase [CK] and lactate dehydrogenase [LDH]) of myocardial injury (Low and 
Ikram 1976), supplementation with Zn2+ may be a useful way of reducing the 
extent of myocardial injury. Zinc pyrithione is a well-known Zn2+ ionophore that 
has been shown to reduce cell susceptibility to oxidative stress induced by H2O2 in 
rats (Oyama et al. 2012). Chanoit et al (2008) demonstrated that in isolated 
hearts, administration of Zn2+ pyrithione reduces injury caused by reperfusion via 
activation of the RISK pathway. Zn2+ pyrithione also decreased the release of LDH 
and CK-MB, reduced collagen content and decreased myocardial infarct size in 
hyperlipidemic rat hearts as well as enhancing the cardioprotective effect of 
ischaemic preconditioning in this setting (Kansal et al. 2015).  
 
1.3 Obesity 
According to the World Health Organisation, obesity is defined as accumulation of 
excess fat (adipose tissue) that presents a risk to health (WHO 2019). Obesity is 
characterised by a build-up of lipids in mature adipocytes of white adipose tissue 
(WAT) leading to an increased number and size of these cells as a consequence of 
energy intake constantly outweighing energy expenditure (Otto and Lane 2005). 
Obesity was once considered a problem only in developed countries however, the 
incidence in low- and middle-income countries is now increasing (WHO 2019). It 
is regarded as a major risk factor for the development of cardiovascular disease 
and has been associated with reduced life expectancy (Wilson et al. 2002; 
Olshansky et al. 2005; Yusuf et al. 2005). The mechanisms connecting obesity 
with cardiovascular disease involves adipokine signalling and changes in circulating 




In obesity, adipose tissue is invaded by macrophages that contribute to insulin 
resistance as well as other disorders related to obesity and these macrophages 
produce tumour necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and other pro-
inflammatory cytokines that interfere with the insulin signalling pathway (Cinti 
2012). Thus, WAT dysfunction is an important factor in the pathogenesis of 
metabolic and cardiovascular diseases. 
In the United States of America, approximately 70% of adults are grouped as 
either overweight or obese in comparison to 40 years ago when it was less than 
25% (Lavie et al. 2009). Body mass index (BMI) is the most commonly used 
anthropometric tool to classify obesity (Table 1.2). However, BMI cannot 
distinguish an elevated body weight due to high levels of lean versus fat body mass 
therefore other anthropometric measures are used to evaluate the degree of 
obesity includes waist circumference (WC) and waist-to-hip ratio (WHR) (Table 
1.2) (Vecchie et al. 2017).   
Obesity and being overweight are associated with chronic and low-grade 
inflammation with irregular production of some pro-inflammatory signalling 
pathways (IL-6, TNF-α, and C-reactive protein (CRP)) (Bulló et al. 2003; Costarelli 
et al. 2010). Chronic, subclinical inflammation is one pathophysiological status 
contributing to the increased risk of atherosclerotic disease associated with 
adiposity (Festa et al. 2001).  
Table 1.2 Definition of obesity by anthropometric measurements (adopted from Vecchie 
et al. 2017). 
BMI WHO classification 
BMI < 18.5 km/m2 Underweight BMI 30–34.9 kg/m2  Class I obesity 
BMI 18.5–24.9 kg/m2          Normal weight BMI 35–39.9 kg/m2 Class II obesity    
BMI 25–29.9 kg/m2 Overweight           BMI > 39.9 kg/m2 Class III obesity (morbid) 
Waist circumference 
Men > 102 cm           Women > 88 cm 
Waist to hip ratio 





1.3.1 Adipose tissue 
The adipose tissue is a large organ with a distinct structure and vascular and nerve 
supplies. It is a vital, yet complex and highly active, endocrine and metabolic organ 
that contains adipocytes, immune cells, stromovascular cells, nerve tissue and 
connective tissue matrix that act in concert as an integrated unit (Kershaw and 
Flier 2004). It is vital for energy homeostasis and is distributed throughout the 
body in two morphologically distinct white (WAT) and brown (BAT) adipose tissue 
depots as described in Table 1.4 (Lefterova and Lazar 2009). 
Adipocytes are specialized cells that play a key role in vertebrate energy 
homeostasis (White and Stephens 2010) and increases in adipocyte number or 
size are a hallmark of obesity. Hence, understanding adipocyte differentiation is 
appropriate for an in-depth knowledge into the pathogenesis of metabolic diseases 
including obesity.  
 
1.3.2 Adipogenesis 
Adipogenesis is the process by which mature adipocytes develop from fibroblast-
like preadipocytes which then differentiate into insulin-responsive and lipid-laden 
adipocytes (Lefterova and Lazar 2009). This process occurs through numerous 
stages (Figure 1.5; Table 1.3) involving a cascade of transcription factors, 
including peroxisome proliferator-activated receptor gamma (PPARγ), 
CCAAT/enhancer-binding proteins (C/EBPs) and SREBP-1 (Gregoire et al. 1998; 
Lefterova and Lazar 2009; White and Stephens 2010). Interactions between 
individual cells, or between cells and the extracellular environment, control growth 
and differentiation of preadipocytes with extracellular matrix proteins and 
preadipocyte factor-1 involved (Gregoire et al. 1998). The key steps in 
adipogenesis are summarised in Table 1.3.  
 
1.3.3 The secretory function of white adipose tissue (WAT) 
The main cellular components of WAT are mature adipocytes. As the store house 
for triacylglycerols (TAGs) and the main long-term fuel reserve in mammals, the 
WAT has a significant impact on plasma lipid levels, glucose uptake rates and 




leptin, adiponectin, and cytokines (TNF-α and IL-6) which control numerous 
physiological processes in the body including appetite, glucose metabolism, 
inflammatory responses and blood pressure (Leftorova and Lazar 2009).   
Table 1.3: Key steps of adipogenesis and their characteristics (adapted from Lefterova 
and Lazar 2009). 
Key steps of adipogenesis Characteristics 
Mesenchymal precursor Proliferation 
Differentiate into several lineages 
Committed preadipocyte Proliferation 
Committed to differentiate along adipocyte 
lineage 
Fibroblast-like morphology  
Growth-arrested preadipocyte Unable proliferation due to contact inhibition 
Mitotic clonal expansion  Initiation of C/EBPβ and C/EBPδ expression and 
activity  
Series of cell divisions (i.e. mitotic clonal 
expansion) 
Re-entry into the cell cycle induced by hormonal 
stimulation  
Terminal differentiation Cell-cycle arrest 
Induction of C/EBPα and PPARγ expression 
Transcriptional activation of adipocyte genes  
Mature adipocyte  Signet-ring morphology: large lipid droplet 
occupies majority of cell volume.  
High expression of adipocyte genes  






Figure 1.5: An overview of phases in adipocyte differentiation. Pref-1, preadipocyte factor-
1; C/EBP (β and α), enhancer binding protein; PPAR-g, peroxisome proliferator-activated 
receptor-g; ECM, extracellular matrix; FA, fatty acid (adapted from Gregoire et al. 1998).  
 
Table 1.4: Functions of white and brown adipose tissue (adapted from Otto and Lane 
2005; Tang et al. 2008; Lefterova and Lazar 2009; Rosen and Spiegelman 2014). 
White adipose tissue (WAT) Brown adipose tissue (BAT) 
Unilocular lipid-filled adipocytes that 
store energy in the form of 
triacylglycerol during times when input 
exceeds expenditure. 
Multilocular adipocytes that specialize 
in breakdown of stored lipid into free 
fatty acids when energy is required. 
Predominant type of fat in humans 
(adults) that store excessive caloric 
intake in the form of lipid. 
Burn lipids through non-shivering 
thermogenesis and generates heat in 






Leptin, a 16,000 molecular-weight adipocyte-specific hormone, has a variety of 
biological functions, including the control of appetite and energy balance (crucial 
hypothalamic signal) and eliciting a proinflammatory immune response (Trayhurn 
and Beattie 2001; Trayhurn and Wood 2004; Trayhurn 2005). It acts on the limbic 
system (hypothalamus) bringing about a state of satiety by stimulating dopamine 
uptake and activating the sympathetic nervous system, thus reducing the desire 
to eat via the locus coeruleus nucleus leading to an increase in resting energy 
expenditure (Fernández-Sánchez et al. 2011). It is primarily made and secreted 
by mature adipocytes. Leptin improves insulin sensitivity by inhibiting lipogenesis 
and stimulating lipolysis, thereby resulting in reduction of intracellular lipid levels 
in pancreatic beta cells, liver and skeletal muscle (Ehrhart-Bornstein et al. 2003; 
Fernández-Sánchez et al. 2011). Elevated levels of leptin are found in animal 
models of obesity and human obesity (Gregoire et al. 1998). In conditions of 
weight loss, circulating levels reduce, causing a reduction in the levels of obesity-
associated inflammatory markers in plasma (Hukshorn et al. 2004).  
Leptin has also been shown to stimulate the release of TNF-α and NO from 
epididymal fat pads in vitro, which suggests important roles in both inflammation 
and the regulation of blood flow throughout the adipose tissue (Mastronardi et al. 
2002). It also promotes oxidative stress and stimulates the proliferation and 
migration of vascular smooth muscle and endothelial cells, suggesting a role in the 
development of cardiovascular disease (Fernández-Sánchez et al. 2011). 
 
1.3.4.2 Adiponectin 
Adiponectin is expressed and secreted by differentiated adipocytes (Fernández-
Sánchez et al. 2011) and assists in regulating energy homeostasis, and glucose 
and lipid metabolism (Sikaris 2004; Trayhurn 2005). In contrast to other 
adipokines, and leptin in particular, adiponectin expression and plasma 
concentrations are decreased in disease conditions presenting with both insulin 
resistance and obesity, such as Type 2 diabetes (Arita et al. 1999; Trayhurn and 
Beattie 2001; Fernández-Sánchez et al. 2011). Adiponectin is considered to 




2007) and high levels of this adipokine are associated with weight loss (Sikaris 
2004; Fernández-Sánchez et al. 2011).  
 
1.3.4.3 Tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) 
TNF-α was the first inflammatory cytokine shown to be expressed in and secreted 
by white adipocytes and is a key regulator of the synthesis of IL-6 (Chiellini et al. 
2002). It is primarily made by lymphocytes, monocytes and skeletal muscle, when 
TNF-α is produced in large amounts, it contributes to the pathogenesis of obesity-
related metabolic syndrome (Hotamisligil et al. 1995; Fernández-Sánchez et al. 
2011). Mature white adipocyte size is regulated by TNF-α, therefore the larger the 
adipocytes the more TNF-α produced, which in turn initiates changes to limit 
adipocyte size or to induce apoptosis (Stephens and Pekala 1991; Hotamisligil et 
al. 1995). 
IL-6 is produced by adipocytes, endothelial cells, macrophages, immune cells, 
fibroblasts and skeletal muscle cells and has many functions which includes 
defence, tissue damage and proinflammatory properties (Fonseca-Alaniz et al. 
2007; Fernández-Sánchez et al. 2011). In adult humans, the amount of IL-6 in 
circulation correlates with the BMI, carbohydrate intolerance and insulin 
resistance, while in experimental animals IL-6 promotes gluconeogenesis and 
glycogenolysis thereby increasing triglycerides (TG) levels while it inhibits 
glycogenesis (Fernández-Sánchez et al. 2011).  
 
1.3.5 Cardiac energy metabolism in obesity 
Although FAs and glucose are the main energy source for the normal heart, in 
obesity there is an increase in FA oxidation due to the inhibition of glycolysis, which 
suppresses glucose oxidation and leads to high levels of circulating free FAs 
(Lopaschuk et al. 2007); this creates an imbalance between FA uptake and 
oxidation, leading to lipid accumulation in the heart (cardiac lipotoxicity) (Chiu et 
al. 2001). With this state of impaired glucose oxidation, even if there is normal 
glucose uptake there is a higher inflow of glucose via the pentose phosphate shunt 
(resulting in ROS formation and lipid peroxidation) (Gupte et al. 2006) and the 




advanced end products of glycosylation (AGEs) (Cooper 2004).  Together these 
negatively affect myocardial energy metabolism, diastolic function and contractility 
(Lopaschuk et al. 2007). Mitochondrial dysfunction also occurs as a result of the 
energy switch, causing accumulation of ROS (through the inability of the 
mitochondria to minimise the superoxide generated) which dysregulates Ca2+ 
homeostasis in cardiomyocytes (Harmancey et al. 2008). One main mechanism 
whereby the hearts responds to its high fat environment is through FA-mediated 
activation of the transcription factor PPARα (fatty acid oxidation regulator) 
(Harmancey et al. 2008). 
 
1.3.6 Adipokine levels in obesity and cardiac energy metabolism 
Obesity causes an increase in leptin and a decrease in adiponectin alongside its 
effects on the secretion of other adipokines like resistin, which affects multiple 
signalling pathways as well as FA metabolism in the heart (Hug et al. 2004; Yildiz 
et al. 2004; Lopaschuk et al. 2007; Blüher 2012). Leptin and adiponectin act on 
the heart to influence various cellular functions, including alterations in fat 
metabolism and cell growth (Ahima and Flier 2000; Friedman 2004; Hug et al. 
2004; Yildiz et al. 2004; Blüher 2012). Adiponectin knockout mice have been 
shown to develop greater infarct sizes following ischaemia/reperfusion and the 
latter is associated with increased TNF-α expression and myocyte apoptosis, 
suggestive of a cardioprotective role for adiponectin (Shibata et al. 2005). 
Furthermore, the high levels of leptin seen in obesity are thought to offer 
protection via oxidation of FAs and interrupting the de novo ceramide synthesis 
pathway preventing apoptosis in cardiomyocytes (Unger 2005). The protective 
effect of adiponectin is thought to be via activation of cyclooxygenase-2 (COX-2) 
in cardiac myocytes and its anti-ischemic effect is exerted via angiogenesis 
stimulation and high quantity of endothelial NO production (Ouchi et al. 2004).  
 
1.3.7 Obesity, obesity paradox and cardiovascular disease (CVD) 
Some overweight and obese patients have shown an improved cardiovascular (CV) 
outcome in comparison to leaner ones; this phenomenon is known as the “obesity 




connected to high risk of CVD (Kenchaiah et al. 2002) but surprisingly obesity 
paradox studies have also shown that overweight and obese individuals with CVD 
experience a better outcome than their leaner counterparts (Lavie et al. 2003; 
Kalantar-Zadeh et al. 2004; Oreopoulos et al. 2010). A study carried out by 
Horwich et al (2001) showed that 4 groups (n= 1,203) of patients categorised 
according to their BMI (underweight :n=164, recommended weight :n=692, 
overweight :n=169 and obese :n=179) who had CVD but did not display any 
difference in their survival rates and the high rate of death amongst patients in 
the study was not related to obesity. Indeed, rather surprisingly, the patients who 
had higher BMI’s displayed a trend of improved survival, giving the impression that 
obesity may be associated with a more favourable outcome (Horwich et al. 2001). 
Normally CVD has been shown to be a consequence of obesity not related to blood 
pressure (BP), age, glucose and lipid levels and these effects increase the risk of 
coronary heart disease (CHD) (Lavie et al. 2014). However, a study carried out by 
Keller et al (2018) showed that obese patients with MI aged 70 years or older had 
a decreased death rate following hospital admission compared to their non-obese 
counterparts, although the obese patients with MI were more intensively treated 
suggesting that as part of the reason for better survival. Iglesias et al (2009) 
recorded larger infarct sizes after AMI in obese subjects (compared to lean 
counterparts) contradicting the obesity paradox. The inconsistencies amongst 
studies could be due to: 1) the anthropometric parameter used to classify obesity 
as BMI is not considered the best predictor of CVD though the most common 
method used to define obesity, 2) the levels of visceral adipose tissue causing 
different levels of chronic inflammation, or 3) different nutritional status and 
micronutrient levels of the individual. 
 
1.4 Oxidative stress (OS) in obesity 
Obesity can induce oxidative stress by the generation of ROS via different 
mechanisms. The first of these is via mitochondrial and peroxisomal oxidation of 
FAs (Fernández-Sánchez et al. 2011; Habib et al. 2015) and nitrotyrosine in the 
coronary endothelium (Galili et al. 2007). Another being the over-consumption of 
oxygen, generation of free radicals in the mitochondria during mitochondrial 




factors influence the susceptibility to OS and this affects the antioxidant status or 
free oxygen radical generation. For example, increases in adipose tissue (obesity), 
cause a dramatic decrease in the activities of the antioxidant enzymes such as 
glutathione peroxidase (GPx), SOD, and catalase (CAT) in the body (Amirkhizi et 
al. 2010; Fernández-Sánchez et al. 2011). Lipoprotein oxidation and plasma lipid 
peroxidation are also markers of OS as free radicals also target lipids (Couillard et 
al. 2005). It has been reported that obesity may induce systemic OS leading to an 
irregular production of adipokines, thus contributing to the development of 
metabolic syndrome (Esposito et al. 2006; Galili et al. 2007). Antioxidant defence 
markers are negatively correlated with both the amount of body fat and central 
obesity (Chrysohoou et al. 2007). 
 
1.4.1 Role of Zn2+ in oxidative stress 
According to Marreiro et al (2017) ‘’Oxidative stress is a metabolic dysfunction that 
favours the oxidation of biomolecules, contributing to the oxidative damage of cells 
and tissues’’ and this leads to the progression of several chronic diseases for 
example cardiovascular diseases. The function of Zn2+ as an antioxidant reduces 
the effect of oxidative stress and as such it regulates gene expression and gives 
structural stability to cell membranes (Marreiro et al. 2017). In the cell membrane, 
Zn2+ competes with iron and copper, inhibits the enzyme NADPH-oxidase and 
decreases hyperglycemia and chronic inflammation (Cruz et al. 2015). Under 
normal conditions, Zn2+ is bound to MT (free radical or ROS scavenger) however, 
in oxidative stress it is released from metallothionein-zinc complex and 
redistributed into cells to carry out its antioxidant actions (Özcelik et al. 2012). MT 
also binds to copper regulating its homeostasis in tissues (Özcelik et al. 2012). In 
diabetic mice, Zn2+ supplementation has been found to induce the expression of 
cardiac MT preventing diabetic cardiomyopathy (Wang et al. 2006). Increased 
inflammatory responses (cytokines) have been seen in endothelial cells as a result 
of Zn2+ deficiency and this has been associated with increased cellular oxidative 
stress whereas Zn2+ supplementation gives protection against vascular damage 
(Marreiro et al. 2017). The relationship between chronic low-grade inflammation 




transcription factors like NF-κB have been shown to induce the generation of ROS, 
thus releasing inflammatory cytokines (Marreiro et al. 2017).  
Adipokines regulate obesity and adipose tissue secretes adipokines which in turn 
generate ROS (Habib et al. 2015). The raised inflammatory state and reduced 
antioxidant capacity in obesity increases the risk of developing atherosclerosis, 
which subsequently increases the risk of both AMI and stroke (Saper and Rash 
2009). Moreover, insufficient dietary intake of Zn2+ may increase the risk of 
inflammation and OS (Bruno et al. 2007) and reduce SOD activity in people who 
are overweight and obese (García et al. 2009; Costarelli et al. 2010). Zn2+ has also 
been shown to be involved in brain cell apoptosis caused by hypoxia or ischaemia 
(Wang et al. 2015) and the prevention of apoptosis (Hennig et al. 1996). This 
difference in Zn2+ apoptotic activity could be due to the physiological and 
pathological conditions of these cells and ultimately the amount of zinc inside in 
the cell (Franklin and Costello, 2009). Knowing that Zn2+ plays a role in protecting 
against OS, its deficiency may enhance the development of CVD (Beattie and Kwun 
2004; Ou et al. 2013).  
 
1.5 Statement of aims and objectives 
The overarching aim of this work is to highlight and explore the relationship 
between dietary Zn2+ intake and the development of CVD. To this end, two studies 
have been carried out:  
A. To understand the impact of a chronic combined suboptimal Zn2+ and high 
fat diet on cardiac antioxidant status (GSH content and Cu/Zn-SOD activity).  
The effect of the diet on body weight, adipose tissue weight, liver weight, and 
the ratios of these tissues to body weight was also determined in the study. 
B. To understand the impact of acute severe Zn2+ depletion, achieved in vivo 
through dietary intervention or in vitro through Zn2+ chelation with TPEN, on 
the extent of injury in the heart following a period of ischaemia/reperfusion on 
cardiac antioxidant capacity (GSH and Cu/Zn-SOD activity) or induced 














































2.1 Tissue homogenisation 
Heart tissues were homogenised in 10 ml of the appropriate homogenization buffer 
per gram of tissue using a Teflon homogenizer. Homogenates were centrifuged (4 
degrees) at 10,000 g for 15 minutes and the supernatant was removed, divided 
into aliquots and stored at either -80oC (myocardial Zn2+ and Cu/Zn-SOD) or -20oC 
(GSH and caspase) depending on the assay to be carried out. 
 
Table 2.1: Homogenization buffers used 
Myocardial Zn2+ and 
Cu/Zn-SOD assay 
Caspase 3 activity assay GSH assay 




onic acid) buffer - pH 
7.2 
Ice cold 25mM HEPES ((4-(2-
hydroxyethyl)-1-
piperazineethanesulfonic acid) 
buffer - pH 7.4  









5mM EDTA   
(Ethylenediaminetetraacetic 
acid) 
2mM EDTA  
(Ethylenediaminetetraa
cetic acid) 
210mM mannitol 2mM DTT (Dithiothreitol) 0.1M phosphate 







2.2 Protein determination 
The Bradford assay is used to determine the amount of protein in samples tested. In 
an acidic environment, proteins bind to Coomassie Brilliant Blue G-250 dye causing 
a rise in the dye’s absorbance (470nm to 595nm) and this is read off from 





Tissue homogenates were thawed at room temperature in readiness for protein 
quantification. Bovine serum albumin (BSA) standards were prepared in PBS over a 
wide concentrations range (0.01-1.5mg/ml) and mixed thoroughly using a vortex. 
Ten μL of the buffer (blank), standard or sample was added to an Eppendorf tube 
and 500μL of Bradford reagent added and mixed by vortexing. Two hundred μL of 
each standard and samples were pipetted into duplicate wells of a 96-well plate and 
incubated for 5 minutes at room temperature. Absorbance was read at 595nm using 
a BioTek MQX200 UQuant Microplate Reader. A standard curve was created by 
plotting the concentration of the standard used against the absorbance values 
corrected by the blank. The concentration of proteins in each sample was calculated 
by using the equation obtained from the plotted standard curve (linear regression). 
First of all, absorbance values for the samples were corrected by subtracting the 
value of the blank  
(Average absorbance of blank concentrations (1+2)  
After which the equation y = ax + b was used.  
Where y is the derived absorbance, a is the slope and x is the concentration.  
Therefore, x = y – b / α.  
 
2.3 Tissue Zinc Assay  
Cardiac Zn2+concentrations were determined using a commercial zinc assay kit 
(Sigma Aldrich – MAK032).  The principle behind the assay is that Zn2+ ions binds to 
a ligand resulting in a product which is measured using the BioTek MQX200 UQuant 
Microplate Reader at 560 nm and this product is proportional to the quantity of Zn2+ 
present. Standards were prepared from assay kit using 0 (blank), 1, 2, 3, 4 and 5 
nmole/well of already prepared Zn2+ standard. Thawed samples were first subjected 
to the Bradford assay to quantify protein content and samples were subsequently 
diluted to a concentration of 0.5mg protein/ml. Samples and standards (0-5 
nmol/well). Fifty µl of samples and standards were pipetted into 96-well plates and 
200μL of Zn2+reagent mix (4 parts Zn2+ reagent and 1 part Zn2+reagent 2) were 
added to each well. Samples were mixed well by pipetting, covered with foil to 
protect from the light and incubated for 10 minutes at room temperature prior to 
reading absorbance at 560nm.  
The amount of Zn2+present in the samples was determined from the standard 





Concentration of zinc (nmoles/μL or mM) = Sa/S  
 
Where Sa=Amount of Zn2+ in unknown sample (nmole) determined from the 
standard curve and S=Sample volume (μL) added to reaction well.  
 
2.4 Caspase 3 activity  
Myocardial Caspase 3 activity was determined using a commercial kit (Sigma 
Aldrich – CASP-3-C). Caspase 3 activation is a marker of the induction of apoptosis 
(programmed cell death). The underlying principle of this assay is to measure the 
conversion of the Caspase 3 substrate N-Acetyl-Asp-Glu-Val-Asp p-nitroanilide 
(Ac-DEVD-Pna) to p-nitroaniline. Homogenised samples were thawed, protein 
content quantified using the Bradford assay and sample concentrations 
subsequently normalised to 0.5mg protein/ml. Caspase 3 substrate (Ac-DEVD-
pNA) stock solution (20mM) was prepared by dissolving the already prepared 
Caspase 3 substrate which is in powder form in 1.2 ml of DMSO to make a stock 
solution of 2mM. p-Nitroaniline (pNA) standards (10-200μM) were prepared in 
assay buffer (50mM HEPES buffer pH 7.4 containing 1.0mM EDTA, 10mM DTT, 
0.1% Chaps, 100mM NaCl, 10% glycerol). All standards and samples were added 
to 96 well plate in duplicate and 10µL of 2mM Ac-DEVD-pNA subsequently added 
to wells with samples. Plates were covered in tinfoil and initially incubated for 90 
minutes at 37oC however because the signal was low, the plate was left and further 
incubated for up to 24 hours (as per the assay instructions for samples with low 
signals), and absorbance read at 405nm (t-value of 1,440). Caspase 3 activity was 
calculated in μmol pNA released per minute per ml of tissue lysate/supernatant 
based on the formula:  
 
Activity; μmol pNA/minute/ml = μmol pNA x d  
                                                       t x v  
Where;  
v - Volume of sample in ml, d – Dilution factor, t – Reaction time in minutes (i.e. 
1,440) 
The activity in µmol/minute/ml converted and expressed as picomoles of the product 






2.5 Glutathione (GSH) Assay  
Total GSH content was determined using a Cayman chemical Glutathione Assay Kit 
(catalogue number: 703002). This assay employs an enzymatic recycling technique. 
In this technique, Glutathione reductase is used for quantifying the GSH. GSH’s 
sulfhydryl group reacts with DTNB (5,5’-dithio-bis-2-(nitrobenzoic acid) producing 
TNB (5-thio-2-nitrobenzoic acid) which is yellow in colour. GSTNB (mixed disulphide: 
GSH and TNB) produced is further reduced by glutathione reductase thus recycling 
the GSH and producing more TNB. TBN production rate is directly proportional to the 
recycling reaction and also to the sample’s GSH concentration. Absorbance is 
measured using a BioTek MQX200 UQuant Microplate Reader at 405nm. 
 
Homogenised samples were, thawed and protein content quantified (Bradford assay) 
and normalised to 0.5mg/ml for all samples. Samples were then deproteinated to 
reduce protein content to a minimum in order to avoid particle interferences as well 
as sulfhydryl groups interference with proteins present in the assay. 
To deproteinate, equal volumes of both samples and MPA (metaphosphoric acid) 
reagent (5g in 50 ml of water) were added together and mixed by vortexing. The 
mixture was left to stand at room temperature for 5 minutes, then centrifuged at 
2000g for 2 minutes. Thereafter, the pH was adjusted by adding 50μl of TEAM 
Reagent (4M triethanolamine solution) to 1 ml of the deproteinated samples and 
vortexed immediately. The Assay Cocktail was prepared by mixing MES Buffer 
(11.25ml), reconstituted Cofactor Mixture (0.45ml), reconstituted with enzyme 
Mixture (2.1ml), water (2.3ml) and reconstituted DTNB (0.45ml) in a 20ml vial. 
GSSG standards (under these assay conditions 1 mole of GSSG is reduced by 
glutathione reductase to produce 2 moles of GSH) were prepared in the concentration 
range of 0–8μM (equivalent to 0-16µM of GSH). Using a 96 well plate, 150μl of the 
prepared assay cocktail was added to each well containing both standards and the 
samples, the plate covered with tinfoil, and incubated on an orbital shaker for 25 
minutes at room temperature before the absorbance was read at 405nm using a 
microplate reader. 
  
Total GSH = [Absorbance at 405nm - (y-intercept)] x 2 x Sample dilution  






2.6 Cu/Zn-SOD activity  
A commercial superoxide dismutase activity kit (Cayman Chemical catalogue 
number: 706002) was used to carry out this assay. The principle behind this assay 
is superoxide radicals being detected by xanthine oxidase and hypoxanthine using 
triazolium salts. A SOD unit is said to be the enzyme amount which is required to 
exhibit 50% superoxide radical dismutation. Although the assay kit is not specific to 
Cu/Zn-SOD, to specifically measure the Cu/Zn-SOD activity the samples were 
homogenized then subjected to three steps of centrifugation (10,000g for 15 minutes 
at 4OC) to separate mitochondrial SOD from cytosolic SOD, whereby the cytosolic 
SOD is retained in the supernatant.  The Cu/Zn-SOD-containing supernatant was 
then stored at -20oC for subsequent analysis.  
 
Samples were thawed and protein content quantified and normalised to 0.5mg/ml 
for all samples. 10μl of samples and standards (0 - 0.05U/ml l SOD Activity) were 
put into 96 well plates and 200μl of dilute radical detector was added. Thereafter, 20 
μl of xanthine oxidase was added to the plate which was then covered with foil to 
protect from light and incubated for 30 minutes on a shaker at room temperature 
prior to reading absorbance at 460nm.  
 
SOD (U/ml) = [(sample LR- y-intercept) x 0.23] X sample dilution  
                                      Slope                 0.01 
  
















3: Study 1 Impact of high fat diet (HFD) on cardiac antioxidant levels 




3.1 Introduction:  
In an animal experimental setting, low Zn2+ status, combined with consumption of a 
diet high in cholesterol and saturated fat, has been shown to promote the 
development of atherosclerosis (Beattie et al. 2012). In that study, both wildtype 
(WT) and apolipoprotein E knockout (ApoE-/-) mice were given a HFD with varying 
levels of Zn2+ for 6 months to determine the effects of suboptimal (3 and 8 mg/kg) 
or optimal (35 mg/kg) Zn2+ levels on the development of vascular inflammation 
and arterial plaque development (Beattie et al. 2012). The animals were studied 
over a 6-month period with results showing that suboptimal dietary Zn2+ intervention 
promoted inflammation of the vessels and increased plaque formation and 
development of the lesion (atherosclerosis) implicating a relationship between high 
fat diet and Zn2+ deficiency in CVD.  
 
The present study looked at the impact of suboptimal Zn2+ status alongside a high 
fat diet on cardiac antioxidant status. The tissues for this work were obtained from 
a bio-bank generated as part of the study of Beattie et al (2012) which included 
three sub-optimal dietary zinc levels of 3, 5 and 8mg/kg. All body, liver and white 
adipose tissue weights used for the present study were provided by Prof. John 
Beattie’s team. For the tissue analyses the 5mg/kg Zn2+ group was used as there 
was sufficient tissue to obtain satisfactory sample sizes, while the other sub-optimal 
zinc groups had very few tissue samples available. 
 
3.1.1 Aim:  
In light of the relationship between dietary Zn2+ intake and development of CVD, 
which can ultimately lead to the development of AMI and subsequent myocardial 
injury, the primary aim of this study was to understand the impact of a combined 
suboptimal Zn2+ and high fat diet on cardiac antioxidant status. To address this 
question, heart tissue from WT mice fed high fat diet for 15 and 25 weeks, stored in 
a biobank generated by the above study by Beattie et al (2012), was tested for 
Cu/Zn-SOD activity and GSH content. The present study also determined the effect 
of this dietary intervention on body weight and both adipose tissue and liver weight 







3.2 Methods:  
The tissues used in this project were obtained from an animal study carried out by 
Beattie et al (2012). In this study, 5 weeks old male C57BL/6 mice were fed custom 
made semi-synthetic diet by Harlan-Teklad (Indianapolis, IN, USA) containing high 
saturated fat (21% w/w) and high cholesterol (0.15%) with either 35 mg/kg Zn2+ 
(zinc adequate; n=10-15) or 5mg/kg Zn2+ (suboptimal zinc; n=10) for 15 or 25 
weeks (chronic dietary intervention). The composition of these diets is detailed in 
Table 3.1. Animals were euthanised following either 15 or 25 weeks of dietary 
intervention. Mice were anaesthetised with sodium pentobarbital (1g/kg body 
weight; Euthatal; Merial Animal Health, Harlow, UK) via intraperitoneal injection and 
exsanguinated under terminal anaesthesia. Total GSH content and Cu/Zn-SOD 
activity were measured in heart samples from mice using commercially available 
assay kits, as detailed in Chapter 2. Details of body weight, WAT and liver weights 
were also provided to determine WAT and liver to body weight ratios. 
 
Table 3.1: basic composition of the high‐fat, high‐cholesterol, western‐type diet by Harlan‐
Teklad (Indianapolis, IN, USA) (adapted from Beattie et al. 2012). 
Components Dietary Zn (5 and 35 mg/kg) 
 
     grams  
  
Egg white solids, spray‐dried          212 
  
Corn starch          75 
  
Maltodextrin          75 
  
Cellulose          46.2 
  
Anhydrous milkfat          210 
  
Cholesterol           1.5 
  
Mineral mix, Zn deficient (81264)           25.7 
  
Calcium Phosphate, dibasic            3.0 
  
Chromium Potassium Sulfate, dodecahydrate          0.02 
  
Vitamin mix (40060)           10.0 
  
Biotin          0.004 
  







Diet was supplemented with 1% ZnSO4.7H2O in sucrose and was adjusted to achieve a Zn2+ 
content for the 5 mg/kg and 35 mg/kg. Diets were also supplemented with sucrose which 




For all datasets, values are expressed as mean ± s.e.m of n animals/tissue samples.  
Differences between groups were determined by Two way Analysis of Variance with 
Tukey’s post-hoc test to allow comparison between all experimental groups.  
Statistical significance was accepted when P<0.05. 
 
 
3.3 Results:  
3.3.1 The impact of suboptimal dietary Zn2+ on body weight in mice 
subjected to either 15 or 25 weeks of high fat feeding.   
Chronic exposure to suboptimal (5 mg/kg) dietary Zn2+ levels and high fat diet in 
mice did not significantly influence body weight (BW) compared with time-matched 
mice fed a Zn2+ adequate – (35 mg/kg) diet (Figure 3.1).   
 
 
Figure 3.1: The impact of suboptimal Zn2+ status on body weight changes in mice subjected 
to either 15 or 25 weeks of high fat feeding with altered dietary Zn2+ i.e. adequate (35 mg/kg) 
Zn2+and suboptimal (5 mg/kg), respectively. All data are expressed as mean ± SEM. 
Statistical significance was determined using a two-way ANOVA and Tukey’s post-hoc test 









3.3.2 The impact of suboptimal dietary Zn2+ status on white adipose tissue 
(WAT) weight in mice subjected to either 15 or 25 weeks of high fat 
feeding 
Chronic exposure to suboptimal (5mg) dietary Zn2+ levels and high fat diet did not 
significantly influence WAT weights between either the level of Zn2+ diet (5 and 35 
mg/kg diet) or duration of diet intervention (15 and 25 weeks; Figure 3.2).   
 




















Figure 3.2: The impact of suboptimal Zn2+ status on white adipose tissue (WAT) in mice 
subjected to either 15 or 25 weeks of high fat feeding with altered dietary Zn2+ i.e. adequate 
(35 mg/kg) Zn2+ and suboptimal (5 mg/kg), respectively. All data are expressed as mean ± 
SEM. Statistical significance was determined using a two-way ANOVA and Tukey’s post-hoc 





3.3.3 The impact of suboptimal dietary Zn2+ status on WAT:BW ratio in 
mice subjected to either 15 or 25 weeks of high fat feeding 
Chronic exposure to suboptimal (5 mg/kg) dietary Zn2+ levels and high fat diet in 
mice did not significantly alter the animal white adipose tissue and body weight 
ratio between either the level of Zn2+ diet (5 and 35 mg/kg) or duration of diet 



























Figure 3.3: The impact of suboptimal Zn2+ status on white adipose tissue body weight 
ratio in mice subjected to either 15 or 25 weeks of high fat feeding with altered dietary 
Zn2+ i.e. adequate (35 mg/kg) Zn2+ and suboptimal (5 mg/kg), respectively. All data are 
expressed as mean ± SEM. Statistical significance was determined using a two-way ANOVA 




3.3.4 The impact of suboptimal dietary Zn2+ status on liver weight (LW) 
and LW:BW ratio in mice subjected to either 15 or 25 weeks of high fat 
feeding.  
Chronic exposure to suboptimal (5 mg/kg) dietary Zn2+ levels and high fat diet for 
25 weeks increased liver weights compared with the Zn2+ adequate (35mg/kg) fed 
and time-matched groups (P<0.01; Figure 3.4). Whereas in the 15 weeks animal 
groups, no difference in LW was observed for either exposure to suboptimal (5 
mg/kg) dietary Zn2+ or Zn2+ adequate (35 mg/kg).  
Furthermore, LW:BW ratio (Figure 3.5) showed no significant differences between 
the suboptimal Zn2+ groups and the controls following 15 weeks of dietary 
intervention (Figure 3.5). However, LW:BW ratio was significantly increased in 
animals fed a high fat diet with suboptimal dietary Zn2+ for 25 weeks compared to 
mice on an equivalent diet for 15 weeks or control animals on a Zn2+ adequate diet 






Figure 3.4: The impact of suboptimal Zn2+ status on liver weight in mice subjected to 
either 15 or 25 weeks of high fat feeding with altered dietary Zn2+ i.e. adequate (35 mg/kg) 
Zn2+and suboptimal (5 mg/kg), respectively. All data are expressed as mean ± SEM. For 
this study, statistical significance was determined using a two-way ANOVA and Tukey’s 





Figure 3.5: The impact of suboptimal Zn2+ status on liver/body weight ratio in mice 
subjected to either 15 or 25 weeks of high fat feeding with altered dietary Zn2+ i.e. adequate 
(35 mg/kg) Zn2+and suboptimal (5 mg/kg), respectively. All data are expressed as mean ± 
SEM. For this study, statistical significance was determined using a two-way ANOVA and 
Tukey’s post-hoc test. There was statistical significance comparing 5 mg/kg Zn2+ at 15 and 








3.3.5 The impact chronic feeding of a combined suboptimal Zn2+ and 
high fat diet on myocardial GSH content.  
Chronic exposure to suboptimal (5 mg/kg) dietary Zn2+ levels and high fat diet did 
not significantly alter cardiac levels of total GSH compared with controls (Zn2+ 
adequate – 35 mg/kg) at either 15 or 25 weeks (Figure 3.6). However, levels of 
total GSH were significantly reduced (P<0.01) by approximately 50% in the Zn2+ 
adequate group (35 mg/kg) at 25 weeks compared with 15 weeks (Figure 3.6). 
GSH levels in the 25 week suboptimal Zn2+ group were similarly lower than the 
matching 15-week group, although this did not reach statistical significance 
(P=0.11; Figure 3.6). 
 
 
Figure 3.6: The impact of suboptimal Zn2+ status on cardiac GSH following high fat feeding 
with altered dietary Zn2+ levels (i.e. adequate (35 mg/kg) and suboptimal (5 mg/kg) Zn2+) 
for either 15 or 25 weeks. All data are expressed as mean ± SEM. For this study, statistical 
significance was determined using a two-way ANOVA and Tukey’s post-hoc test **indicates 





3.3.6 The impact of chronic feeding of a combined suboptimal Zn2+ and 
high fat diet on myocardial Cu/Zn-SOD activity.  
Chronic exposure to suboptimal (5 mg/kg) dietary Zn2+ levels and high fat diet in 
mice did not significantly alter cardiac Cu/Zn-SOD activity compared with controls 
(Zn2+ adequate – 35 mg/kg; Figure 3.7). However, when comparing Cu/Zn-SOD 
activity between the two time points (15 and 25 weeks), an increase in Cu/Zn-
SOD activity was observed in the 25 week, compared to the 15 week, groups 




Overall, there was an approximate five-fold increase in Cu/Zn-SOD activity 




Figure 3.7: The impact of suboptimal Zn2+ deficiency status on cardiac SOD following high 
fat feeding with altered dietary Zn2+ levels (adequate (35 mg/kg) and suboptimal (5 
mg/kg)) for either 15 or 25 weeks. All data are expressed as mean ± SEM. Statistical 
significance was determined using a two-way ANOVA and Tukey’s post-hoc test 





3.4 Discussion:  
The primary aim of this study was to understand the impact of a combined 
suboptimal Zn2+ and high fat diet on cardiac antioxidant status. The key findings 
from this study were that suboptimal intake of dietary Zn2+ per se has no effect on 
either total GSH content or Cu/Zn-SOD activity in cardiac tissue. However, the 
duration of high fat feeding does appear to differentially influence both GSH levels 
and Cu/Zn-SOD activity. Moreover, altered dietary Zn2+ levels do not significantly 
affect body weight or the amount of white adipose tissue of the animals after 25 
weeks of high fat feeding, while suboptimal Zn2+ was associated with increased liver 








3.4.1 The impact of duration of dietary intervention on antioxidant 
biomarkers (GSH and Cu/Zn-SOD) in the heart.  
While the results of this study have shown that, in the presence of high fat feeding, 
suboptimal Zn2+ does not influence either the amount of GSH or Cu/Zn-SOD 
activity in the heart, an extended duration of the dietary intervention (25 vs 15 
weeks) was observed to induce changes (decreased GSH content and increased 
Cu/Zn-SOD activity) in both the dietary Zn2+ deficient and Zn2+ adequate groups. 
These changes could be due to the duration of the high fat diet, to the age of the 
animal, or a combination of the two.  
 
Ageing is associated with an increase in free radical generation, which causes 
oxidative damage that affects the integrity and functions of cells (Kim et al. 2002; 
Cao et al. 2004). The present study has shown that myocardial levels of GSH in 
both suboptimal and Zn2+ adequate animals (5 mg/kg and 35 mg/kg) at 25 weeks 
of feeding were found to be lower than that of the 15 weeks dietary intervention 
groups. This finding is consistent with a study by Kim et al (2002) which measured 
the levels of serum GSH from male Fischer 344 rats aged 13 (young) and 31 (old) 
months and demonstrated the presence of low levels of serum GSH in old rats 
compared to young rats, suggesting that aging increases oxidative stress. Cao et 
al (2004) carried out a study on 5 and 24-month-old Sprague-Dawley rats to 
establish a functional link between excess oxidative stress and age-related decline 
in steroidogenesis. This study showed that among the non-enzymatic antioxidants, 
the level of GSH was drastically reduced during aging, as well as the catalytic 
activity of Cu/Zn-SOD in testicular Leydig cells of old rats (Cao et al. 2004).  GSH 
levels have also been shown to reduce with age in the brain of rats (aged 2, 10 
and 20-months) (Samarghandian et al. 2015), while Jung and Henke (1996), 
studied developmental changes in antioxidants biomarkers in the liver and kidney 
of male Wistar rats of different ages (1, 2, 3, 6, and 12 months) and observed that 
there was a continuous decline of hepatic GSH content in older rats. Taken together 
these findings are consistent with the present observation that age negatively 
affects the GSH content of the heart.  
 
Zn2+ is essential for the activity of SOD1 (Cu/Zn-SOD), which is a highly efficient 




al. 2018). Similar to GSH, Cu/Zn-SOD activity was not affected by chronic 
exposure to suboptimal Zn2+ for either 15- or 25-weeks. This is in contrast to 
findings reported in the literature where Zn2+ deficiency has been shown to result 
in significantly reduced Cu/Zn-SOD activity in cardiac tissue (Pucheau et al. 1995; 
Barandier et al. 1999) and plasma (Huang et al. 2018).  Interestingly, and in 
contrast to the effects on GSH, aging was found to increase Cu/Zn-SOD activity in 
cardiac tissue in the present study. Again, this is not in alignment with previous 
reports (albeit in different tissues), since Gomes et al. 2009 showed an increase 
in the expression of the SOD isoforms 2 and 3, but no change in SOD1 (Cu/Zn-
SOD) levels, in the renal cortex of old (52-week-old) versus young (13-week-old) 
rats. 
 
3.4.2 Impact of high fat diet on antioxidant systems (GSH and Cu/Zn-
SOD). 
A key promoter of obesity and cardiovascular disease is high fat diet (HFD), which 
itself has been shown to cause an increase in ROS production and induce 
alterations in the oxidative stress status of the vascular system (Reil et al. 1999; 
Sweazea et al. 2010; Mayyas et al. 2017). Moreover, increased ROS production 
can lead to a decrease in GSH antioxidant levels (Birben et al. 2012). Studies have 
shown that HFD differentially impacts on antioxidant defences. For example, a 
short-term (10 weeks) dietary intervention study to determine the effects of 
different diets, where the control group had 5% fat, 0.5% NaCl, the HFD group 
were given 25% fat, 0.5% NaCl and the high salt group given 5% fat, 8% NaCl, 
on myocardial oxidative stress status in young (6–10 weeks old) Sprague Dawley 
rats showed no changes in the levels of GSH after a 10 week dietary intervention 
period (Mayyas et al. 2017). Another study in four-month-old female obesity prone 
mouse strains (C57BL/6J, DBA/2J and AKR/J) fed a HFD similarly showed no 
changes in GSH levels in the liver after 10 weeks (short term) feeding (Norris et 
al. 2016). Due to the lack of normal fed controls in the present study, the individual 
effects of increasing fat content in diet alone on antioxidant status in the heart 
cannot be assessed. In contrast, in a 16 week study of HFD-induced obesity in 
white albino rats, examination of oxidative stress markers in tissues (liver, heart 
and kidney) found that, compared to animals fed normal chow, GSH levels were 
significantly decreased in both liver and renal tissues, while in heart tissue GSH 




the trend of the current study, none of the studies above looked at prolonged HFD 
diet intervention, and so it is difficult for a direct comparison with the present 
study. Although GSH content reduced with time in the present study (high fat fed 
mice) their comparison to levels in normal chow mice over the same period is 
unknown. However, the fact that most studies show that diet does not appear to 
alter GSH levels (compared to normal fed animals) it is perhaps unlikely to that 
the lower levels seen with a longer diet duration in the present study is due to diet 
duration, rather most probably an age-related effect. 
 
The present study showed that mice subjected to prolonged (25 weeks) high fat 
feeding had significantly higher cardiac levels of Cu/Zn-SOD activity than mice fed 
HFD for 15 weeks. Very few studies have determined the impact of HFD on Cu/Zn-
SOD activity, however a study in rats that assessed the impact of a 36-week HFD 
on skeletal muscle gene expression and mitochondrial function, showed that HFD 
altered transcript levels of 18 genes: HFD increased the expression of genes 
involved in stress response  but reduced expression of free-radical scavenger 
enzymes including Cu/Zn-SOD, resulting in reduced DNA repair/metabolism 
(increased DNA damage) (Sreekumar et al. 2002).  
 
3.4.3 Influence of suboptimal dietary Zn2+ status on body, adipose and 
liver tissues weights in older mice. 
In general, obese individuals have high body weights typically because they have 
higher amounts of body fat, although changes in body weight can correspond to 
changes in body water, fat, and/or lean tissue content. The data from this animal 
study showed no correlation between body and WAT weight and dietary Zn2+ 
status. This is consistent with a study conducted by Tallman and Taylor (2003) 
that investigated the effects of dietary fat and Zn2+ on adiposity in C57BL/6J mice 
and showed that, after 16 weeks of dietary treatment, body weights were similar, 
irrespective of dietary zinc or dietary fat content.    It has been proposed that over 
a long time (aging animals), the animal becomes better suited to a condition of 
low Zn2+ intake (Tallman and Taylor 2003) which could explain the current finding 
that there is no difference in between the 5 mg/kg and the 35 mg/kg dietary Zn2+ 




In contrast, liver weights in the sub-optimal Zn2+ group, at 25 weeks, were higher 
than the weight of livers from mice fed the a sub-optimal Zn diet for 15 weeks, or 
a Zn2+ adequate diet for either 15 or 25 weeks. This implies that prolonged 
suboptimal Zn2+ results in changes at the level of the liver, possibly through 
increased fat accumulation in the liver.  Although this was not assessed in the 
present study, this could be measured either by Oil Red-O staining and histological 
analysis or by measuring lipid content.   While few studies have looked at the 
effects of Zn deficiency on liver metabolism, Reeves and O'Dell, 1983 carried out 
a study using Male Wistar rats to demonstrate the effect of Zn deficiency on 
glucose metabolism in meal-fed rats (a low-Zn diet:>1mg/kg Zn and an adequate-
Zn diet; 100mg/kg), and rats fed ad libitum on either a low-Zn (>1mg/kg) diet or 
an adequate-Zn diet (100 mg/kg) for 3 weeks. The results showed that Zn 
deficiency caused a slight, but significant, decrease in glucose incorporation into 
liver fatty acids and a significant increase in glucose incorporation into liver 
glycogen of meal-fed fats compared to meal-fed Zn adequate rats  Moreover, liver 
size and the fatty acid pool size in the livers of the Zn-deficient, rats was lower 
than that of the zinc-adequate controls, which the authors proposed resulted from 
an increased rate of turnover of fatty acids by the liver of the Zn-deficient rats.   
Although this study showed that the liver was a major site of adaptation to Zn2+ 
deficiency, when expressed per unit tissue the response was not as large as that 
found in adipose tissue, presumably due differences in the effect of insulin on 




3.4.4 Limitations of the Study and Further Work 
The absence of a group of animals fed a normal fat diet in the present study makes 
it difficult to conclude whether prolonged feeding with high fat diet causes changes 
in antioxidant biomarkers’ levels in the heart. However, dietary intervention 
studies which compared normal fed and high fat fed groups have shown that there 
is no effect of high fat diet on cardiac antioxidants (GSH and Cu/Zn-SOD) following 
short term (10 weeks) feeding (Norris et al. 2016; Mayyas et al. 2017). Although 
the present study compared HFD groups of animals on short term (15 weeks) and 




intervention arm of this study are in line with the literature. The trends in the 25 
week diet groups are comparable to those in the literature (Sreekumar et al. 2002) 
hence this is suggestive that high fat feeding induces a gradual decline of 
antioxidant capacity over time. Although literature implies that the effects seen on 
anti-oxidant status are due to ageing, to test this in future, studies performed with 
different groups of age-matched animals receiving normal or high fat diet for either 
short or long term intervention would allow determination of the impact of both 
age (within diets) and duration of HFD diet feeding (differences between diets). 
 
3.5 Conclusion 
In conclusion, sub-optimal Zn2+ had no effect on two cardiac biomarkers of 
antioxidant status, and there have been no previous studies to this effect. 
However, the changes seen in the cardiac biomarkers of antioxidant status 
measured are likely to be due to ageing rather than duration of diet, and again 
























4: Study 2: Impact of acute severe dietary and invitro (TPEN) Zn2+ 













4.1 Introduction:  
In post MI patients, cardiac and plasma Zn2+ levels have been reported to decline 
within the first 3 days (mean fall = 76-83 µg/lOO ml) after infarction and then 
return to normal (normal range=90-118 µg/lOO ml.) levels by the tenth day of 
disease (Low and Ikram, 1976) which may suggest that the loss of Zn2+ 
contributes, at least in part, to cardiac injury. Cardiac GSH levels increased, while 
malondialdehyde (marker of tissue injury) levels in the heart decreased following 
Zn2+ supplementation before I/R in rats (Ozyıldırım et al. 2017). Following acute 
myocardial I/R, Zn2+ plays several protective roles, viz protection following 
cardiomyocyte acute redox stress; wound healing, avoidance of myocardial 
damage triggered inflammatory processes and cardiac stem cell maintenance (Lee 
et al. 2015). In vivo, Zn2+ deficiency is linked to a more pronounced pro-
inflammatory status (Choi et al. 2018). On the contrary, in vitro studies show that 
cellular Zn2+ depletion occurs as a result of a decreased function of the endothelial 
cell barrier (Hennig et al. 1992). However, no work was present in the literature 
that explored the underlying effects of acute dietary Zn2+ deficiency and its impact 
on an I/R insult in comparison with acute TPEN-induced Zn2+ deficiency. As a 
consequence, a series of experiments was conducted in my supervisor’s laboratory 
to address this gap; this piece of work was a part of that study.  The experiments 
were carried out in a rat animal model and this piece of work was recently 




A project in my supervisor’s laboratory aimed to determine the impact of severe Zn2+ 
depletion, achieved in vivo through dietary intervention or in vitro through Zn2+ 
chelation with N,N,N′,N′-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN), on 
the extent of injury to the heart following a period of I/R. The present study aimed 
more specifically to determine whether these interventions influence cardiac 
antioxidant capacity (GSH levels and Cu/Zn-SOD activity) or induced apoptosis 
(Caspase 3 activation) in the heart. 
 
4.2 Methods:  
Male Sprague–Dawley rats (200–250g; approximately 8 weeks old) were purchased 




subjected to two-week dietary intervention periods: Zinc adequate (ZA) diet (35 
mg/kg Zn2+) fed ad libitum, Zinc deficient (ZD) diet (<1 mg/kg Zn2+), ZA Pair-fed 
(PF) controls. The PF controls were included to ensure that any changes seen were 
not simply due to reduced weight gain that results from severe Zn2+ depletion. 
Animals were anaesthetised via intraperitoneal injection of pentobarbital sodium salt 
(100 mg/kg body weight; Sigma Aldrich), blood collected via cardiac puncture, the 
heart quickly removed and arrested in ice cold Kerbs Henseleit buffer (KHB; 25 mm 
NaHCO3, 1·18 mm KH2PO4, 2·41 mm MgSO4, 2·52 mm CaCl2, 119 mm NaCl, 4·7 mm 
KCl and 10·88 mm glucose; pH 7·4) prior to mounting on a Langendorff-perfusion 
system. Isolated heart studies were carried out in which regional ischaemia was 
induced by placing and tightening a ligature around the left coronary artery (LCA) 
for 30 minutes, followed by a 2h reperfusion period (release of the ligature). A group 
of sham hearts were also employed, whereby they were subjected to the same 
period of perfusion (150 minutes) without the induction of ischaemia or 
reperfusion.  
 
To compare the effects of in vivo dietary Zn restriction with in vitro Zn depletion, 
two further groups of hearts from normal-fed rats were used.  To induce Zn 
depletion 10µM of the Zn2+ chelator TPEN was added to the perfusion medium 
(infusion rate of 100µl/minutes through the aortic aortic cannula) from 10 minutes 
before the induction of ischaemia / occlusion and maintained until the end of the 
experiment.  
 
Upon completion of the ischaemia/reperfusion protocol, ventricular tissue was snap 
frozen in liquid nitrogen for biochemical analysis of myocardial Zn2+ content, caspase 
activity, total GSH content and Cu/Zn-SOD activity using commercially available 
assay kits as described in Chapter 2. The isolated heart experiments were conducted 
by Dr Karen Skene in my supervisor’s laboratory.  
 
Statistical analysis 
A one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test was used to 
perform comparisons using one group as a control.  For the dietary intervention 
study, the PF group was the control, while for the in vitro Zn2+ depletion study the 





4.3 Results:  
 
4.3.1 The impact of acute dietary Zn2+ deficiency and myocardial I/R on 
both Zn2+ content and Caspase 3 activity in rat hearts.  
 
Acute dietary Zn2+ deficiency was not associated with any variation in myocardial 
tissue Zn2+ levels across all groups (ZA, PF, ZD) (Figure 4.1A), whereas, the PF 
rats (control group) in comparison to the ZD group displayed a significant rise in 
cardiac caspase-3 activity (Figure 4.1B). Therefore, the ZD rats had lower caspase 
levels than the PF rats.  However, the ZA rats also had lower caspase activity 
levels, suggesting that this is a characteristic of pair feeding. 
 
 
Figure 4.1: The impact of acute Zn2+ deficiency and myocardial I/R on myocardial Zn2+ 
content (A) and Caspase 3 activity (B). Data are expressed as mean ± SEM and significance 
determined as P<0.05 using a one-way ANOVA and Dunnett’s post-hoc test; n=3-7. 
*P<0.05 ZD compared with pair-fed (PF) controls. † P<0.05 PF compared with zinc-




4.3.2 The impact of acute dietary Zn2+ deficiency on GSH content in hearts 
subjected to myocardial I/R.  
In rat cardiac tissue there was a statistically significant reduction in the GSH 
content levels in the ZD group compared to the other 2 groups (ZA, PF) which 
seemed not to be affected by the feeding (Figure 4.2). The difference between the 
PF and ZD hearts was due to the Zn2+ deficiency. Similarly, there is no difference 






Figure 4.2: The impact of acute Zn2+ deficiency on GSH content in rat hearts subjected to 
30 minutes regional ischaemia followed by a 2hr reperfusion period. All data are expressed 
as mean ± SEM. Statistical significance was determined using one-way ANOVA and 




4.3.3 The impact of acute dietary Zn2+ deficiency on Cu/Zn-SOD activity 
in hearts subjected to myocardial I/R  
 




Figure 4.3:  
The impact of acute Zn2+ deficiency on Cu/Zn-SOD activity in rat hearts subjected to 30 
minutes regional ischaemia followed by a 2hr reperfusion period. All data are expressed 
as mean ± SEM. Statistical significance was determined using a one-way ANOVA and 







4.3.4 The impact of in vitro acute Zn2+ depletion using TPEN and 
myocardial I/R on Zn2+ content and Caspase 3 activity in rat hearts.   
 
In vitro acute Zn2+ depletion, obtained using TPEN, did not induce any significant 
difference in either myocardial tissue Zn2+ levels or Caspase 3 activity across all 
groups (Sham, Vehicle, TPEN) (Figure 4.4A and B) following I/R.  
 
Figure 4.4: 
Effect of TPEN (10µM) on tissue Zn2+ content (A) and Caspase 3 activity (B) in rat hearts 
subjected to myocardial I/R. Data are expressed as mean ± SEM and significance 
determined using one-way ANOVA and Dunnett’s post-hoc test; n=10. 
 
 
4.3.5 The impact of in vitro acute Zn2+ depletion using TPEN and 
myocardial I/R on GSH content in rat hearts.   
I/R induction displayed a reduced GSH content in both the vehicle and the TPEN 
groups when compared with the sham hearts (Figure 4.5) although not statically 
significant.   
   
 
Figure 4.5:  
Effect of TPEN (10µM) on GSH content in isolated hearts subjected to 30 minutes acute 
regional myocardial ischaemia and 2 h reperfusion. All data are expressed as mean ± SEM. 







4.3.6 The impact of in vitro acute Zn2+ depletion using TPEN and 
myocardial I/R on Cu/Zn-SOD activity in rat hearts.  
I/R induction resulted in reduced Cu/Zn-SOD activity in both the vehicle and the 
TPEN groups when compared with the sham hearts (Figure 4.6). However, in 
hearts given TPEN, there was a significant reduction in Cu/Zn-SOD activity 
compared with control I/R hearts. Comparing the controls, the vehicle control was 




Figure 4.6:  
Effect of TPEN (10µM) on Cu/Zn-SOD activity in isolated rat hearts subjected to 30 minutes 
acute regional myocardial ischaemia and 2 h reperfusion. All data are expressed as mean 
± SEM. Statistical significance was determined as P<0.05 using a one-way ANOVA and 
Dunnett’s post-hoc test (n=10). *P <0.05 compared to vehicle controls. †P <0.05 




The primary aim of this study was to understand the impact of both dietary and in 
vitro acute Zn2+ depletion on Zn2+ levels, Caspase 3 activity, and antioxidants 
biomarkers in rat hearts subjected to acute regional myocardial ischaemia and 
reperfusion.  The main findings for this study are that dietary Zn2+ depletion was 
associated with reduced cardiac GSH levels, while Cu/Zn-SOD activity was not 
affected by dietary Zn2+ intake. In contrast, in vitro acute Zn2+ depletion with TPEN 
reduced Cu/Zn-SOD activity, but not GSH content. Neither method of Zn2+ depletion 
had any effect on myocardial Zn2+ content. Caspase 3 activity was observed to be 
decreased in ZD rats (relative to PF rats) but was not significantly different from 





4.4.1 Tissue Zn2+ content and Caspase 3 activity following acute dietary 
Zn2+ deficiency  
Assessment of Zn2+ levels in the heart showed that severe dietary Zn2+ restriction 
had no significant effect on cardiac Zn2+ levels. Although I did not perform plasma 
Zn2+ analysis, the plasma from these rats was analysed by another member of my 
supervisor’s lab (K Skene) and the results showed circulating levels of Zn2+ in the 
ZD group was significantly lower than (<50%) those in both ZA and PF rats 
(Skenet et al., 2019). Thus theere was evidence of severe Zn2+ deficiency in these 
animals. Considering the severity of the extent of dietary Zn2+ depletion, one would 
have expected lower myocardial Zn2+ levels compared to Zn2+-adequatehearts, but 
this was not the case. However, the results obtained are in agreement with those 
obtained from a study conducted by Coudray et al (1993), who also showed that 
acute dietary Zn2+ deficiency (4 ppm Zn2+ for the  zinc-deficient group and 60 ppm 
Zn2+ for the standard diet group for 3 weeks) caused no notable difference in 
myocardial tissue Zn2+ levels. Similarly, studies in rats with less severe Zn 
depletion (22 mg/kg vs 98 mg/kg) or Zn2+ supplementation (214 mg/kg) showed 
no alterations in myocardial Zn (Pucheau et al., 1995).  The findings that cardiac 
levels of Zn2+ are unaffected by marked alterations in extracellular Zn2+ can 
probably be explained by the tight control of Zn2+ in the cardiomyocyte, which is 
due to a combination of the release of Zn2+ from MT stores along with alterations 
in Zn2+ influx/efflux from the cell to maintain levels. Moreover, the accumulation 
of Zn2+ in structures like the sarcoplasmic reticulum of the cardiac cell could help 
to maintain its level in the myocardial cell. (Lee et al. 2015).  
 
Studies by Karagulova et al (2007); Chanoit et al (2008); Viswanath et al (2011) 
all agree that Zn2+ supplementation improves ischaemic injury and prevents 
cardiomyocyte death. Although studies have shown that oxidative stress occurring 
in a dietary Zn2+ deficiency state increases apoptosis in vascular tissue (Allen-
Redpath et al. 2013), there is no current literature that has examined the impact 
of Zn2+ deficiency on apoptosis in the heart. Being an integral component of 
proteins, Zn2+ is essential for binding DNA (e.g., p53) and can act as an activator 
or an inhibitor (e.g., caspases) making cell proliferation and cell survival pathways 
intertwined by the addition or withdrawal of protein growth factors like insulin-like 
growth factors, IGF-1 and IGF-2. Zn2+ binds to an active site cysteine to inhibit 




(PKC) (Clegg et al. 2005). The data from the present study has shown for the first 
time that acute dietary ZD does not appear to induce caspase-3 activation in the 
myocardium. However other caspases like caspase 9, although not measured, 
could have activated apoptosis and this could possibly be the explanation to the 
greater degree of infarcts in the rat hearts.   These  caspases would therefore have 
been of interest to look at these in addition to caspase-3.  
 
Endogenous ROS production initiates DNA damage which activates the tumor 
suppressor gene: p53 (p53 is a Zn2+ finger transcription factor that regulates both 
G1 and G2 checkpoints, preventing cells with damaged DNA from proceeding with 
new DNA synthesis or undergoing cell division) (Clegg et al. 2005). This induces 
the intrinsic pathway of apoptosis by causing cytochrome c into the cytosol release 
from mitochondria and this recruits the apoptosome complex (caspase-9 zymogen, 
Apaf-1, and dATP) leading to the auto-catalytic activation of initiator caspase-9 
and cleavage of effector procaspase-3 (Clegg et al. 2005). Glutathione depletion 
by ROS is associated with apoptosis induction and levels have been shown to be 
reduced in culture mediums with the addition o metal chelators like TPEN inhibiting 
caspase activation (Carter et al. 2002).  
 
 
4.4.2 Acute Zn2+ deficiency and myocardial I/R alters antioxidant 
biomarkers in rat hearts 
The results from the present study, demonstrating that the GSH content was 
significantly lower in the dietary Zn2+ deficient groups compared to the other groups, 
is consistent with findings from a study by AL-Rasheed et al(2014) which showed 
that Zn2+ deficiency reduces GSH content due to its consumption at the time of 
scavenging the high levels of free radicals (AL-Rasheed et al. 2014). AL-Rasheed et 
al(2014) looked at GSH amongst other antioxidant enzymes in six groups of rats of 
which one group was Zn-pretreated (30 mg/kg)  for 28 days followed by an induction 
of a MI for 2 days (day 27 day  and 28) and tissue homogenates showed decreased 
levels of GSH (AL-Rasheed et al. 2014). Due to the high myocardial demand of 
oxygen and the ratio of oxidants to antioxidants, any condition that incapacitates the 
antioxidant defence system (i.e. ischaemia/reperfusion) may expose the heart to 





Zn2+ is also essential for the activity of SOD1 (Cu/Zn-SOD) and SODs are highly 
efficient antioxidants that prevent occurrence of free radical induced injury (Huang 
et al. 2018). In the present study, Cu/Zn-SOD activity was not affected in animals 
subjected to acute dietary Zn2+ depletion and this is in agreement with the literature 
as there was no significant change in cardiac SOD levels seen in rats deficient in Zn2+ 
amongst other trace elements (Pucheau et al. 1995; Barandier et al. 1999). Jones 
et al (2003) have previously reported that SOD does not protect against reperfusion 
injury in the intact heart, and so it is likely that it is the reduction in GSH that has 
contributed to the increased infarct size identified in the wider study.. Thus, further 
studies are required to better understand the effect of acute or chronic Zn2+ depletion 
on biomarkers of SOD activity in the heart. 
 
4.4.3 Outcome of I/R following in vitro acute Zn2+ depletion with TPEN 
In the present study, acute Zn2+ depletion with TPEN did not alter the total 
myocardial tissue Zn2+ contentAlthough myocardial Zn2+ levels were not 
significantly affected by TPEN treatment, the concentration of TPEN used was 
previously shown to chelate Zn2+ at this concentration. Paret et al (2007) 
conducted a study using the same concentration as used in the present study and 
found that TPEN caused a dose-dependent reduction cellular Zn2+ content in HaCaT 
keratinocytes (Parat et al. 1997). The difference between the present findings in 
the whole heart and those in cell preparations could potentially be explained by 
changes in Zn2+ transporter activity in the heart in situ causing preservation of 
cardiac Zn2+. Thus, TPEN chelation may block attempts by the cell to adjust Zn2+ 
homeostasis in the face of declining intracellular Zn2+ concentrations causing a loss 
of Zn2+ (Clegg et al. 2005). Additionally, since TPEN chelates free Zn2+ and the 
assay used measured total (i.e. bound and free zinc) it is possible that the assay 
was not sensitive enough to detect the loss of free Zn2+.  
 
The wider study conducted with same tissues by my supervisor’s team as published 
in the literature (Skene et al 2019) showed findings of increased 
ischaemia/reperfusion injury with TPEN.  This is in agreements with a study by 
Ferdinandy et al., who studied the effects of similar concentrations (10 µM) of TPEN 
ischaemic and reperfusion arrhythmias and observed a reduced incidence of 




However, although the concentration of TPEN used in this study gives it a higher 
affinity for Zn2+ than other cations (Ca2+) the effects of TPEN is most likely from 
the other cations being removed. In I/R endogenous Zn2+ has been reported to be 
harmful and cause cell death by activating extracellular signal-regulated 
kinase/glycogen synthase kinase β (ERK/ GSK3β) (Lin et al. 2011). Endogenous 
Zn2+ has been reported to be cardioprotective through its action on signalling 
process in nitric oxide (NO) via intracellular messenger (Jang et al. (2007). 
Endogenous Zn2+ is also known to play an important role in maintaining redox 
status within tissues (Oteiza, 2012).  Knowing that TPEN is a Zn2+ chelator, one 
would have thought that it would give a significant reduction in myocardial Zn2+ 
level compared to the controls but this was not the case.  
In the present study, treatment with TPEN prior to myocardial I/R did not alter 
Caspase 3 activity compared to the controls. However, results from a study carried 
out by Pang et al (2013) showed that following treatment with TPEN, Caspase 3 
was activated although this was through inhibition of ERK in the hippocampal 
neurons.  
A reduction in Cu/Zn-SOD activity (Figure 4.6) was observed following I/R induction 
compared with the sham hearts. TPEN reduced Cu/Zn-SOD activity compared to 
vehicle treated hearts (Figure 4.6). Cu/Zn-SOD is a Zn2+ dependent isoform thus 
post reperfusion, it is not likely to contribute to tissue preservation. Cu/Zn-SOD has 
been proven not to protect against I/R rather the interstitial levels of the extracellular 
SOD (Omar and McCord 1991).   
The results obtained from the TPEN arm of the study is different to what was seen in 
the dietary intervention arm. Though in vitro endogenous Zn2+ depletion with TPEN 
demonstrated an increase in infarct size, however, the increase in infarct size due to 
dietary deficiency was associated with a reduced Cu/Zn- SOD activity since there 
was preservation of the GSH levels and no evidence of caspase-3 activation. 
However, it is known that endogenous SOD-1 is not the only Zn-dependent isoform 
of SOD although has demonstrated to be an unlikely contributor to post-reperfusion 
tissue preservation. In the vascular wall, between the endothelium and the extra 
cellular space and the cells of the smooth muscles is where the extracellular SOD 
(SOD-3) is most available and this plays a crucial role in the regulation of the vascular 
redox state(Strålin et al. 1995) and it is indicated  that the SOD-3 (interstitial levels) 
confer protection against I/R injury rather than SOD-1 (Omar and McCord, 1991). 




Cu/Zn-SOD activity (i.e. SOD-1 and SOD-3), the infarct size increase might likely be 
due to an inhibition of SOD-3, rather than SOD-1 activity. 
 
Conclusions 
The key results from these studies are that both acute dietary Zn2+ deficiency and 
acute in vitro Zn2+ depletion worsen the extent of myocardial injury resulting from 
I/R via different mechanisms. Dietary Zn2+ deficiency results in a decrease in the 
content of myocardial GSH which is the likely cause of damage to the cardiac tissue 
following I/R (as reported in Skene et al., 2019) due to the induced oxidative stress. 
However, in vitro Zn2+ depletion is likely to worsen I/R injury because of the reduced 
availability of SOD to mop up the superoxide radicals, again resulting in increased 
oxidative stress. These results have demonstrated that sever dietary Zn2+ 
insufficiency poses a problem and may lead to a worse outcome following acute 
myocardial ischaemia, causing increased morbidity and mortality. However the 
results from the TPEN studies, where different mechanisms are induced, suggest that 
further research into the role of Zn2+ in cardiovascular physiology and 




















5.1 General Discussion:  
As mentioned earlier, even though the human body contains about 2–4g of Zn2+, 
only 12–16μmol/L exists as a mobile Zn2+ pool in plasma. This low plasma 
concentration of Zn2+ is due to its tight binding to proteins (MT) and zinc transport 
proteins (Jansen et al. 2012). Zn2+ is involved in the regulation of glutathione 
peroxidase and is a cofactor for SOD hence its maintenance in the cell is crucial to 
adequate antioxidant system function (Marreiro et al. 2017).  
 
Studies pertaining to the role of Zn2+ in cardiac protection tend to focus more on 
the effect of exogenous Zn2+ supplementation. However, endogenous Zn2+ is 
mobilized by NO via its opening of mitochondrial ATP channels and this has been 
shown to offer cardioprotection (Powell et al. 1994; Jang et al. 2007). The 
importance of the role of endogenous Zn2+ in cardiovascular system maintenance 
cannot be over emphasized. A human study, carried out to assess the relationship 
between Zn2+ intake and the prevalence of coronary artery disease (CAD) in urban 
and rural areas in India, showed that urban men and women consume lower 
amounts of Zn2+ compared to their rural counterparts and have a significantly 
higher prevalence of CAD, suggesting that the prevalence of CAD is higher in 
individuals with low Zn2+ intake (Singh et al. 1998). There is growing evidence that 
Zn2+ intake is associated with reduced plasma glucose. For example, Chen et al. 
(1997) studied a population of obese (BMI >30 kg/m2) and lean (BMI = 21.2 + 
0.6) individuals free from endocrine disease hence not on any medication, also not 
on any supplement (vitamin or minerals), between the ages of eighteen and 
twenty two and found that the obese individuals had lower fasting plasma Zn2+ 
concentrations ([13.5 + 1.0 vs. 18.1 + 0.9] µmol/L). Another study this time in  
animals also showed that Zn2+ supplementation lowered fasting plasma glucose 
levels in obese mice using eight weeks old male obese C57BL/6J mice and their lean 
controls given 20 mM of ZnCl2 in drinking water for eight weeks (totalling 16 weeks 
of age) and plasma glucose tolerance test (1 g glucose/kg body wt, ip) was measured 
following more than 12 hr of fasting  (Chen et al. 1998). In all, obesity brings about 
changes in the biochemical parameters of Zn2+ and an increase in the production 
of free radicals contributing to OS which eventually leads to low Zn2+ 
concentrations in the plasma, erythrocytes and an increase in the antioxidant 
enzyme (GPx and SOD) activities in tissues (heart, liver, kidney and muscle) (Ferro 




increased demand to fight against the obesity induced free radical (Ferro et al. 
2011). 
 
In the present study, how endogenous Zn2+ depletion induced by in vivo dietary 
deficiency and in vitro removal of intracellular Zn2+ affected the antioxidant 
capacity of the heart was investigated.  The results demonstrated how important 
it is to maintain adequate levels of Zn2+ to protect the heart from developing 
atherosclerotic plaques associated with western type diet or acute myocardial 
infarction. 
 
The dietary interventions in the first study looked at dietary Zn2+ deficiency in 
conjunction with high fat diet where animals (mice) were fed HFD containing either 
35 or 5 mg/kg Zn2+ (adequate and suboptimal Zn2+, respectively) over 15 and 25 
weeks (chronic intervention).Whereas, the second study involved rats that were fed 
standard diets with different Zn2+ compositions (ZA – 35 mg/kg Zn2+, ZD- <1 mg/kg 
Zn2+ and PF) for 14 days (acute intervention) as stated in chapter 4. The acute study 
also looked at Zn2+ depletion achieved via in vitro Zn2+ chelation with TPEN. 
 
Overall, mice subjected to chronic dietary intervention showed more age-related 
effects in the parameters measured: GSH concentration in the older animals (25 
weeks group) showed a significant difference comparing the Zn2+ adequate and 
the suboptimal Zn2+ groups but no difference was observed within the 15 week 
groups (Zn2+ adequate:35 mg/kg vs suboptimal:5 mg/kg). However, the acute 
Zn2+ deficiency study showed better GSH levels in the ZA group compared with 
the ZD and TPEN groups. Zn2+ deficiency has been shown to reduce GSH levels in 
other tissues like the brain (Omata et al. 2012) and the liver (Kojima-Yuasa et al. 
2005) and a reduction in the levels of GSH can cause a harmful effect on 
myocardial tissue following I/R as GSH inhibits tissue injury caused by ROS 
(Chatham et al. 1988; Cheung et al. 2000). 
In both studies, results observed in the Cu/Zn-SOD activity might be due to the 
endogenous production of SOD-1 and this agrees with the literature (Jones et al. 
2003). In study one, an extended duration of the dietary intervention (25 vs 15 




dietary Zn2+ deficiency study) showed similar Cu/Zn-SOD activity in the heart 
tissue in the 3 groups (ZD, PF, and ZA). 
Myocardial Zn2+ content was measured and there was no significant difference in 
the Zn2+ levels which is probably due to the tight regulation of Zn2+ homeostasis 
intracellularly by metallothionein, ZnT and ZIP (Liuzzi and Cousins 2004; Baltaci 
et al. 2018). Hearts treated with TPEN also did not show significant differences in 
Zn2+ content.  
 
5.2: Conclusion 
Reduced or suboptimal intake of dietary Zn2+ differentially affects total GSH 
content in cardiac tissue. More specifically, exposure to acute Zn2+ deficiency 
reduces levels of total GSH whereas chronic exposure does not. On the contrary, 
Cu/Zn-SOD activity is not affected by either acute Zn2+ depletion or chronic 
exposure to a suboptimal Zn2+ level for either 15 or 25 weeks. The primary findings 
from these studies is that, in both studies, suboptimal or acute Zn2+ deficiency 
affect the antioxidant status of the cardiovascular system differently. 
Chronic Zn2+ intake (mouse study) and acute dietary Zn2+ deficiency results in a 
reduction in total GSH content. However, in vitro Zn2+ depletion is affected by the 
partial superoxide scavenging capacity. Altogether, dietary insufficiency of Zn2+ 
has been identified as a risk factor for a worse outcome from cardiovascular 
disease which is linked to an increase morbidity and mortality rates.  
Since Zn2+ deficiency is linked with obesity, and dietary Zn2+ supplementation has 
been shown to reduce the incidence of diabetic cardiovascular complications, a 
similar approach may be applicable to protect against obesity-related enhanced 
risk to cardiovascular disease. Knowing that the percentage of the global 
population that is currently obese (~500M people according to the 2008 WHO 
statistics) and therefore at risk of a cardiovascular disease with a worse outcome 
is on the increase, this makes the morbidity burden huge. Similarly, the global 
incidence of dietary Zn2+ deficiency is high, therefore given the important role of 
Zn2+ in endogenous cardioprotection (SOD1 and the RISK pathway), the potential 




against both the development of obesity and abrogating against severe cardiac 
damage needs exploration.  
Interestingly, to date this piece of work is the first to explore the role of Zn2+ in 
maintaining antioxidant status in the heart with respect to the impact of high fat 
diet on cardiac antioxidant status in wild type mice and the impact of  acute severe 
dietary and invitro (TPEN) Zn2+ depletion on cardiac antioxidant levels in rats 
hearts following myocardial I/R and whether  Zn2+ levels contributes to the extent 
of myocardial injury.. The differences seen in the two experiments in terms of 
antioxidant status is that severe deficiency in rats decreased GSH, while sub-
optimal Zn2+ alongside HFD in mice did not. Therefore, future studies would be 
recommended to determine the impact Zn2+ deficiency would have alongside a 
HFD following injury in other to tie the two studies together. Furthermore, the 
potential value of dietary Zn2+ supplementation in obese people as a means of 
abrogating against I/R injury has not been assessed. Hence, further research is 
needed to explore the molecular mechanisms involved and if Zn2+ supplementation 
may be manipulated and used as a therapeutic tool in obese patients with CVD. A 
novel approach involving Zn2+ supplementation in obese individuals, could 
significantly reduce long term morbidity in an enormous population and therefore 
future therapies may include nutritional supplements for people who have been 
identified as having the genetic or clinical potential to benefit from it.  
Animal models have been used extensively in research with some models providing 
more insight into the pathogenesis of the human disease. The species of animal 
used is determined by several factors. For these present studies, different species 
of rodents where used due to impact they have made following this type of study 
in relation to human health. on the outcome of the experiment. Mice are known to 
be good animal models for arteriosclerosis and obesity which is very similar in 
comparison to humans. Thus this model was used to explore whether high fat diet 
intervention alongside sub-optimal Zn2+ levels influence cardiac anti-oxidant 
status. In contrast, the rat is a well-established model for ischaemia / reperfusion 
injury studies, hence the reason for undertaking these studies in this species. 
In general, the smaller the animal, the more manageable and cheaper the 
experiment although rodents may not adequately reflect the human situation. In 




refinement and replacement. Effort is made to reduce the number of animals 
required for any particular study and experimental design is refined so that it 
causes the least discomfort to the animals and, ultimately, animal models should 
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